bisoprolol has been researched along with Blood Pressure, High in 256 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effect of 12 months of treatment with moxonidine or bisoprolol on telomerase activity (TA) and parameters characterizing the arterial wall state in postmenopausal women with arterial hypertension (AH) and osteopenia." | 9.51 | Influence of Moxonidine and Bisoprolol on Morphofunctional Condition of Arterial Wall and Telomerase Activity in Postmenopausal Women with Arterial Hypertension and Osteopenia. The Results from a Moscow Randomized Study. ( Bazaeva, E; Dudinskaya, E; Eruslanova, K; Kotovskaya, Y; Larina, V; Matchekhina, L; Sharashkina, N; Tkacheva, O, 2022) |
| "The primary aim was to compare sequential nephron blockade (SNB) versus dual renin-angiotensin system blockade (DRASB) plus bisoprolol in patients with resistant hypertension to observe reductions in systolic and diastolic blood pressure (SBP and DBP) levels after 20 weeks of treatment." | 9.51 | Effect of Sequential Nephron Blockade versus Dual Renin-Angiotensin System Blockade Plus Bisoprolol in the Treatment of Resistant Hypertension, a Randomized Controlled Trial (Resistant Hypertension on Treatment - ResHypOT). ( Bonalume Tacito, LH; Cestario, EDES; Cosenso-Martin, LN; da Silva Lopes, V; Fernandes, LAB; Moreno Junior, H; Rubio, TA; Uyemura, JRR; Vilela-Martin, JF; Yugar-Toledo, JC, 2022) |
| " Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension (ResHypOT)." | 9.27 | Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized control ( Cestário, EDES; Cosenso-Martin, LN; Fernandes, LAB; Giollo-Júnior, LT; Landim, MIP; Matarucco, CSS; Moreno, H; Tácito, LHB; Uyemura, JRR; Vilela-Martin, JF; Yugar-Toledo, JC, 2018) |
| "This narrative review evaluates recent evidence from four studies which explore the efficacy, safety, and adherence of FDC bisoprolol and amlodipine in patients with hypertension: one observational study; two randomized clinical trials (RCTs); and one indirect comparison analysis." | 9.22 | A growing evidence base for the fixed-dose combination of bisoprolol and amlodipine to manage hypertension. ( Gaciong, Z; Hostalek-Gottwald, U, 2022) |
| "Spironolactone was the most effective add-on drug for the treatment of resistant hypertension." | 9.20 | Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. ( Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, I; McInnes, G; Morant, S; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B, 2015) |
| "The PATHWAY-2 study, funded by the British Heart Foundation, randomised 335 patients with resistant hypertension (already treated according to guidelines) to sequentially receive 12 weeks of spironolactone (25-50 mg), bisoprolol (5-10 mg), doxazosin (4-8 mg modified release) and placebo." | 9.20 | [PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension]. ( Widimský, J, 2015) |
| "5 mg hydrochorothiazide + 5 mg amlodipine, 86 patients with resistant hypertension were randomized to the add-on 25 mg spironolactone (MRB group, n = 46) or 5 mg ramipril (RASB group, n = 40) groups for 12 weeks." | 9.19 | Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. ( Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF, 2014) |
| "Aim of the study was to assess effect of monotherapy with nebivolol, bisoprolol, carvedilol for 2 months on sexual function in men with arterial hypertension (AH)." | 9.17 | [Effect of monotherapy with nebivolol, bisoprolol, carvedilol on the state of vegetative nervous system and sexual function in men with arterial hypertension]. ( Mustafaev, II; Nurmamedova, GS, 2013) |
| "222 subjects with hypertension who had received coronary angiography examination were involved in the study, 162 in bisoprolol therapy group (96 men, 59%) and 60 in non-bisoprolol group (39 men, 65%)." | 9.17 | Bisoprolol improved endothelial function and myocardium survival of hypertension with stable angina: a randomized double-blinded trial. ( Dong, M; Lin, ZP; Liu, J, 2013) |
| "TY-0201 (TY) is a new drug absorbed by the transdermal delivery system developed for the treatment of hypertension, which contains the free base of bisoprolol fumarate that is widely used." | 9.17 | Comparison of efficacy and safety between bisoprolol transdermal patch (TY-0201) and bisoprolol fumarate oral formulation in Japanese patients with grade I or II essential hypertension: randomized, double-blind, placebo-controlled study. ( Kuwajima, I; Matsuoka, H; Mitamura, H; Saruta, T; Shimada, K, 2013) |
| "To investigate the efficacy and safety of bisoprolol/hydrochlorothiazide (Lodoz) in patients with mild and moderate essential hypertension." | 9.12 | [The clinical efficiency and safety of bisoprolol hydrochlorothiazide in patients with mild to moderate essential hypertension]. ( Jiang, H; Ke, YN, 2006) |
| "To compare the efficacy and tolerability of bisoprolol, enalapril and nifedipine retard in the treatment of mild to moderate essential hypertension." | 9.10 | Efficacy of domestic bisoprolol,enalapril and nifedipine retard in mild to moderate hypertension: a randomized double-blind multicenter clinical trial in China. ( Li, M; Liu, G; Shi, X, 2002) |
| "The aim of the present study was to evaluate the antihypertensive efficacy of the highly beta(1)-selective adrenergic antagonist nebivolol in comparison with bisoprolol in the treatment of mild to moderate essential hypertension." | 9.10 | Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). ( Bodnar, J; Czuriga, I; Edes, I; Fulop, T; Kristof, E; Kruzsicz, V; Riecansky, I, 2003) |
| "25 mg (n = 84) to amlodipine 5 mg (n = 80) in isolated systolic hypertension in patients older than 60 years." | 9.09 | Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. ( Benetos, A; Consoli, S; Dubanchet, A; Safar, M; Safavian, A, 2000) |
| "Bisoprolol, a beta1-selective beta-blocker, was administered to 13 patients with mild to moderate essential hypertension once daily at doses of 5-10 mg for 24 weeks, and its long-term effects on blood pressure and glucose metabolism were investigated." | 9.09 | The effects of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension. ( Hata, T; Miyake, S; Owada, A; Suda, S, 2001) |
| "25 mg of hydrochlorothiazide (HCTZ) given once daily with 5 mg of bisoprolol fumarate can contribute to antihypertensive effectiveness in patients with stage I and stage II (mild to moderate) systemic hypertension; and (2) assess whether this formulation was more effective or possessed a safety advantage over standard monotherapy with bisoprolol or 25 mg of HCTZ." | 9.08 | First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. ( Alemayehu, D; Bryzinski, BS; Burris, JF; Chen, SY; Frishman, WH; Mroczek, WJ; Simon, JS; Weir, MR, 1995) |
| "Quality of life with the selective beta1-blocker bisoprolol and the calcium channel blocker nifedipine as a retard formulation was compared in patients with essential hypertension." | 9.08 | Quality of life comparison between bisoprolol and nifedipine retard in hypertension. ( de Hoon, JN; Van Bortel, LM; van de Ven, LL; Vanmolkot, FH, 1997) |
| "One hundred and six patients in the stage I and stage II of the systemic hypertension (mild to moderate) were given the bisoprolol/hydrochlorothiazide combination once daily and the diastolic and systolic blood pressures were monitored during the 8-week trial." | 9.08 | [Efficacy and tolerance of the bisoprolol/hydrochlorothiazide combination in arterial hypertension]. ( Batlouni, M; Castro, I; Chaves Júnior, Hde C; da Rocha, JC; Feitosa, GS; God, EM; Luna, RL; Maia, LN; Mion, D; Oigman, W; Ortega, KC; Raineri, AM; Ramirez, JA, 1998) |
| "The acute and short-term responses to bisoprolol and to atenolol on systemic and renal hemodynamics and on ambulatory blood pressure (BP) were compared in a randomized double-blind cross-over study including 14 patients with mild to moderate essential hypertension." | 9.07 | Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure. ( Collart, F; Degaute, JP; Leeman, M; Mélot, C; Peeters, L; van de Borne, P; Vandenhoven, G, 1993) |
| " Thirty patients with essential hypertension and left ventricular hypertrophy were studied at baseline after withdrawing all previous treatments and after 6 months of treatment with 5-20 mg of bisoprolol, a new beta-selective agent, to assess its possible action on left ventricular mass." | 9.07 | Effects of bisoprolol on left ventricular hypertrophy in essential hypertension. ( Camacho-Vázquez, C; de Teresa, E; González, M; Tabuenca, MJ, 1994) |
| "A total of 512 patients with mild to moderate essential hypertension were randomized to once-daily treatment with bisoprolol (0, 2." | 9.07 | A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. ( Alemayehu, D; Bryzinski, BS; Coulson, LR; DeQuattro, VL; Dukart, G; Frishman, WH; Goldberg, JD; Koury, K; Mroczek, WJ; Vlachakis, ND, 1994) |
| "Atenolol and bisoprolol, two beta-1-selective blockers, were compared in patients with mild and medium severe hypertension." | 9.07 | [Atenolol and bisoprolol in the treatment of mild and moderately severe hypertension]. ( Prásek, J; Soucek, M; Spinarová, L, 1993) |
| "This study used 24-h ambulatory blood pressure (BP) monitoring to investigate the effectiveness of a novel low-dose combination of bisoprolol/hydrochlorothiazide in adult patients with mild to moderate essential hypertension." | 9.07 | A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension. ( Cardenas, P; Lewin, AJ; Lueg, MC; Targum, S, 1993) |
| "To investigate prospectively the effects of the selective beta 1 adrenoceptor blocker bisoprolol on sexuality of men with hypertension." | 9.07 | Bisoprolol and hypertension: effects on sexual functioning in men. ( Broekman, CP; Haensel, SM; Slob, AK; Van de Ven, LL, 1992) |
| "Blood pressure, heart rate, common carotid and brachial arterial hemodynamics using pulsed Doppler flowmetry and pulse wave velocity determinations were evaluated using a double-blind crossover design versus placebo in 14 patients with sustained essential hypertension treated by the selective beta 1 blocking agent bisoprolol." | 9.07 | Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. ( Asmar, RG; Girerd, XJ; Kerihuel, JC; Safar, ME, 1991) |
| "Forty outpatients (11 men and 29 women) aged between 65 and 85 years (mean age of 68 years) with mild to moderate hypertension [mean systolic/diastolic blood pressure (SBP/DBP) after 2 weeks on placebo of 175/102 mm Hg] were included in a randomized, double-blind, parallel-group study to compare the efficacy and tolerance of 10 mg of bisoprolol once daily (o." | 9.06 | Bisoprolol and nifedipine SR in the treatment of hypertension in the elderly. ( Carretero, J; Garcia, MJ; Garrido, M; Oliván Martinez, J; Pizarro, JL; Rodriguez Botaro, A, 1990) |
| "Twenty-six patients with mild-to-moderate essential hypertension participated in a 6-week outpatient, multicenter, randomized, double-blind, placebo-controlled two-way crossover study to assess the hemodynamic effects of bisoprolol (20 mg QD) at steady state." | 9.06 | Multicenter evaluation of the hemodynamic effects of bisoprolol in patients with mild to moderate hypertension. ( Bryzinski, B; Carr, AA; Desnoyers, M; McKee, B; Nelson, BR; O'Donnell, DM; Prisant, LM; Westcott, RJ; Zinny, MA, 1990) |
| "The aim of the study was to compare the antihypertensive efficacy and safety of a new beta blocker with high beta 1 selectivity, bisoprolol, with captopril in 28 elderly patients, aged over 65 years, with mild-to-moderate essential hypertension (WHO classes I and II)." | 9.06 | A double-blind comparison of bisoprolol and captopril for treatment of essential hypertension in the elderly. ( Alberti, A; Bracchetti, D; Brunelli, A; Cantelli, I; Gradnik, R; Leonardi, G; Orselli, L; Pavesi, PC, 1990) |
| "6 years (32-65 years), with hypertension WHO I-II, were given bisoprolol in doses of 5, 10, and 20 mg." | 9.06 | Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension. ( Frithz, G; Weiner, L, 1986) |
| "The antihypertensive effect and possible adverse effects of bisoprolol were assessed in 96 Japanese patients with mild to moderate hypertension." | 9.06 | Clinical evaluation of bisoprolol in patients with hypertension: interim report. ( Iimura, O; Ikeda, M; Inagaki, Y; Kuramoto, K; Takeda, T, 1986) |
| "The cardioselectivity and hypotensive properties of the beta 1-specific beta-blocker bisoprolol were investigated using a single-dose comparison of 10 and 20 mg bisoprolol, 100 mg atenolol, and placebo in 12 hypertensive asthmatic patients." | 9.06 | The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. ( Chatterjee, SS, 1986) |
| "0, range 37-61 years; eight females) with mild essential hypertension (DBP greater than 90 mm Hg on placebo) completed a randomised, double-blind placebo controlled crossover study comparing the hypotensive effects of bisoprolol (10-20 mg) and atenolol (50-100 mg) each taken once daily." | 9.06 | A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. ( Ioannides, C; Johnston, A; Lewis, R; Maclean, D; McDevitt, DG, 1988) |
| "Bisoprolol reduces systolic and diastolic blood pressures in patients with hypertension for a 24-hour dosing interval and is associated with beneficial hemodynamic effects in patients with myocardial ischemia." | 8.79 | Bisoprolol: is this just another beta-blocker for hypertension or angina? ( Johns, TE; Lopez, LM, 1995) |
| "This study was conducted on the characteristics of PVC in hypertensive patients with left ventricular hypertrophy and aimed to evaluate the effect of bisoprolol on PVC in Vietnamese patients with hypertension and LVH." | 8.31 | The Effect of Bisoprolol on Premature Ventricular Complex in Vietnamese Patients with Hypertension and Left Ventricular Hypertrophy. ( Bao Nguyen, NN; Huynh, MV; Kim Tran, S; Ngo, TH; Ngoc Huynh, HT; Nguyen, TH; Phuong Nguyen, AT; Vo, CT, 2023) |
| "This study assessed the real-life effectiveness of a single-pill combination (SPC) of bisoprolol/perindopril for controlling blood pressure (BP) and symptoms of angina in patients with hypertension and a history of myocardial infarction (MI)." | 8.31 | Effectiveness and Tolerability of Bisoprolol/Perindopril Single-Pill Combination in Patients with Arterial Hypertension and a History of Myocardial Infarction: The PRIDE Observational Study. ( Burtsev, Y; Kobalava, Z; Kvasnikov, B, 2023) |
| " This study assessed the effectiveness and tolerability of bisoprolol/perindopril (Bis/Per) single-pill combination (SPC) in Russian patients with hypertension and coronary artery disease (CAD) treated in routine clinical practice." | 8.02 | Effectiveness and Tolerability of the Single-Pill Combination of Bisoprolol and Perindopril in Patients with Arterial Hypertension and Stable Coronary Artery Disease in Daily Clinical Practice: The STYLE Study. ( Boytsov, SA; Burtsev, YP; Karpov, YA; Khomitskaya, YV, 2021) |
| "Bisoprolol can effectively reduce RHR in Asian CAD patients with comorbid hypertension and hence, improve CCCO without affecting their blood pressure." | 7.96 | Resting heart rate control and prognosis in coronary artery disease patients with hypertension previously treated with bisoprolol: a sub-group analysis of the BISO-CAD study. ( Chen, XP; Chen, YD; Fu, GS; Huang, SA; Kim, DS; Kim, TH; Liu, SW; Ma, TR; Pham, VN; Truong, BQ; Yang, XC; Yang, Y, 2020) |
| "Given that it has been reported that type 2 diabetes mellitus may affect the pharmacokinetics of a large number of drugs and that there are still no published population pharmacokinetic (PopPK) analyses in routinely treated patients with hypertension and type 2 diabetes mellitus as comorbid condition, the aim of this study was to determine PK variability of bisoprolol in 70 Serbian patients using the PopPK approach." | 7.96 | Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension. ( Janković, SM; Jovanović, A; Milovanović, JR; Momčilović, S; Nikolić, VN; Pešić, M; Radojković, D, 2020) |
| "Whether the reduction of heart rate with ivabradine (IVA) could affect sympathetic activation and cardiac innervation in heart failure (HF) remains unknown." | 7.91 | Modulation of Sympathetic Activity and Innervation With Chronic Ivabradine and β-Blocker Therapies: Analysis of Hypertensive Rats With Heart Failure. ( Akiyama, T; Iwanaga, Y; Kakehi, K; Miyazaki, S; Shimizu, S; Sonobe, T; Watanabe, H; Yamamoto, H, 2019) |
| "In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs." | 7.88 | Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. ( Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, IS; McInnes, GT; Morant, SV; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B, 2018) |
| "7 years, 19 men) with uncomplicated hypertension without diabetes were given bisoprolol 5-10 mg." | 7.81 | [The Fixed Combination of Amlodipine and Bisoprolol Eliminates the Effect of -Blockers on Central Pulse Wave in Patients With Arterial Hypertension]. ( Bogomaz, AV; Kobalava, ZD; Kotovskaya, YV, 2015) |
| "To evaluate the efficacy and safety of a fixed-term combination of β-blocker bisoprolol and the calcium antagonist amlodipine in the outpatient treatment of patients with arterial hypertension (AH) and coronary heart disease (CHD)." | 7.80 | [Evaluating the effectiveness of a fixed combination of amlodipine and bisoprolol in ambulatory patients with arterial hypertension and ischemic heart disease]. ( Chesnikova, AI; Kolomatskaia, OE; Safronenko, VA, 2014) |
| "The investigation has been conducted with the aim of studying association between polymorphic marker G1846A of CYP2D6 gene and efficacy and safety of bisoprolol in 64 pregnant women with chronic stage I and II hypertension." | 7.75 | [Efficacy and safety of bisoprolol in pregnant women with chronic arterial hypertension do not depend on genetic CYP2D6 polymorphism]. ( Brytkova, IaV; Ignat'ev, IV; Kazakov, RE; Sokova, EA; Striuk, RI, 2009) |
| "Measurement of levels of hormones of the pituitary-gonadal system, dopplerography of penile arteries and questioning after Vasiltchenko were carried out in 30 men (age 35-55 years) with I-II degree arterial hypertension who received monotherapy with bisoprolol and nebivolol for 2 months." | 7.74 | [Level of hormones of pituitary-gonadal axis, penile blood flow and sexual function in men with arterial hypertension during monotherapy with bisoprolol and nebivolol]. ( Gumbatov, NB; Mustafaev, II; Nurmamedova, GS, 2007) |
| "Study aim was assessment of clinical efficacy of mono therapy with nifedipine SR/GITS and combination of nifedipine SR/GITS and bisoprolol as well as investigation of functional state of sympathoadrenal system (SAS) in pregnant women with arterial hypertension." | 7.74 | [Clinical efficacy of antihypertensive therapy of pregnant women with arterial hypertension with long acting nifedipine and bisoprolol]. ( Brytkova, IaV; Bukhonkina, IuM; Pavlova, LN; Striuk, RI, 2008) |
| "A case of a 60-year-old male patient, suffering from benign prostatic hyperplasia (BPH), with deterioration of lower urinary tract symptoms (LUTS) during antihypertensive treatment with bisoprolol was presented." | 7.73 | Repeated intensification of lower urinary tract symptoms in the patient with benign prostatic hyperplasia during bisoprolol treatment. ( Chodorowski, Z; Hajduk, A; Sein Anand, J, 2005) |
| "The efficacy, safety, and pharmacokinetics of bisoprolol were investigated following oral administration once daily for 12 weeks in hyperreninemic patients with dialysis-refractory hypertension." | 7.70 | Pharmacokinetics of bisoprolol and its effect on dialysis refractory hypertension. ( Hiroshige, K; Iwamoto, M; Kanegae, K; Nakashima, Y; Ohta, T; Ohtani, A; Suda, T, 1999) |
| "Long-term efficacy and safety of the beta1-selective adrenoceptor-blocking agent bisoprolol was investigated in 164 patients with mild to moderate essential hypertension who had already been treated successfully with bisoprolol once daily for 1 year in preceding studies." | 7.68 | Three years of experience with bisoprolol in the treatment of mild to moderate hypertension. ( Buchner-Möll, D; Giesecke, HG, 1990) |
| "The authors administered to 10 patients with mild hypertension a single dose of 10 mg bisoprolol (Concor-Merck) during bioimpedance control of changes of the cardiac index and peripheral vascular resistance after an interval of 3 and 24 hours following administration of the drug." | 7.68 | [The effect of a single dose of Bisoprolol on changes in blood pressure and hemodynamic indicators in patients with mild hypertension]. ( Marek, D; Oral, I; Vareka, I, 1992) |
| "The authors administered to 10 patients with mild hypertension a single dose of 10 mg bisoprolol (CONCOR-Merck) during bioimpedance control of changes of the cardiac index and peripheral vascular resistance during an isometric load after an interval of 3 and 24 hours following administration of the drug." | 7.68 | [The effect of a single dose of Bisoprolol on changes in blood pressure and hemodymic indicators in patients with mild hypertension during loading]. ( Marek, D; Oral, I; Vareka, I, 1992) |
| "Fifty patients with essential hypertension WHO Grades I-II have been treated for 3 months with bisoprolol, a new selective beta blocker, in doses up to 40 mg once daily." | 7.67 | Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. ( Frithz, G; Weiner, L, 1987) |
| "The aim of our study was to estimate clearance of bisoprolol and reveal the factors that could influence its pharmacokinetic (PK) variability in hypertensive patients on hemodialysis, using the population PK analysis." | 6.82 | Population Pharmacokinetics of Bisoprolol in Hemodialysis Patients with Hypertension. ( Andric, BR; Dimitrijevic, ZM; Jankovic, SM; Jevtovic-Stoimenov, T; Milovanovic, JR; Nikolic, VN; Petrovic, DS; Sokolovic, MJ; Zivanovic, S, 2016) |
| "Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months." | 6.78 | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. ( Dobrokhod, AS; Kushnir, SM; Radchenko, GD; Sirenko, YM; Torbas, OO, 2013) |
| "Hypertensive left ventricular hypertrophy (HTN LVH) is associated with almost threefold increased risk of ventricular tachycardia (VT)/ventricular fibrillation (VF)." | 6.72 | Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk. ( Koracevic, G; Lovic, D; Sakac, D; Stojanovic, M; Zdravkovic, M, 2021) |
| " A once-daily dosing schedule was evaluated by comparing bisoprolol's antihypertensive effectivness and safety at 24 h postdose and 3 h postdose, the latter time intended to correspond to peak effectiveness." | 6.67 | Bisoprolol, a once-a-day beta-blocking agent for patients with mild to moderate hypertension. ( Alemayehu, D; Blumenthal, JB; Bryzinski, BS; Davidov, ME; Koury, KJ; Simon, JS; Singh, SP; Vlachakis, ND, 1994) |
| "Bisoprolol and atenolol were similar in the black (10 +/- 5/9 +/- 3 mm Hg [n = 22] and 10 +/- 6/6 +/- 3 mm Hg [n = 13], respectively) and young (15 +/- 1/11 +/- 1 mm Hg [n = 84] and 16 +/- 2/10 +/- 1 mm Hg [n = 66], respectively) groups." | 6.67 | Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group. ( Kazempour, MK; Lefkowitz, MP; Neutel, JM; Ram, CV; Smith, DH; Weber, MA, 1993) |
| "of bisoprolol was added to the maximal dose of nitrendipine (20 mg o." | 6.67 | Nitrendipine in the therapeutic management of elderly hypertensive patients: results of a multicenter trial. Andalousian Hypertension Group. ( Aranda, P; Fernandez, JA; Lopez de Novales, E; Lopez, S, 1992) |
| " The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs." | 6.67 | A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ( Dixon, MS; Sheridan, DJ; Thomas, P, 1990) |
| "Bisoprolol is a new beta 1-selective beta-blocking agent with a plasma half-time of 10-12 h and without partial agonist properties." | 6.66 | Antihypertensive effects of bisoprolol during once daily administration in patients with essential hypertension. A dose-ranging study with parallel groups. ( Frithz, G; Weiner, L, 1986) |
| " Bisoprolol is effective, well-tolerated and safe in the treatment of hypertension." | 6.66 | Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study. ( Frithz, G; Hosie, J; Lithell, H; Selinus, I; Weiner, L, 1987) |
| "Bisoprolol is a beta 1-adrenoceptor antagonist with no partial agonist (intrinsic sympathomimetic) activity or membrane stabilising (local anaesthetic) activity." | 6.37 | Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. ( Lancaster, SG; Sorkin, EM, 1988) |
| "However, orthostatic hypotension (OH) is sometimes caused by BBs." | 5.56 | Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T; Sano, T, 2020) |
| "To compare the effect of 12 months of treatment with moxonidine or bisoprolol on telomerase activity (TA) and parameters characterizing the arterial wall state in postmenopausal women with arterial hypertension (AH) and osteopenia." | 5.51 | Influence of Moxonidine and Bisoprolol on Morphofunctional Condition of Arterial Wall and Telomerase Activity in Postmenopausal Women with Arterial Hypertension and Osteopenia. The Results from a Moscow Randomized Study. ( Bazaeva, E; Dudinskaya, E; Eruslanova, K; Kotovskaya, Y; Larina, V; Matchekhina, L; Sharashkina, N; Tkacheva, O, 2022) |
| "The primary aim was to compare sequential nephron blockade (SNB) versus dual renin-angiotensin system blockade (DRASB) plus bisoprolol in patients with resistant hypertension to observe reductions in systolic and diastolic blood pressure (SBP and DBP) levels after 20 weeks of treatment." | 5.51 | Effect of Sequential Nephron Blockade versus Dual Renin-Angiotensin System Blockade Plus Bisoprolol in the Treatment of Resistant Hypertension, a Randomized Controlled Trial (Resistant Hypertension on Treatment - ResHypOT). ( Bonalume Tacito, LH; Cestario, EDES; Cosenso-Martin, LN; da Silva Lopes, V; Fernandes, LAB; Moreno Junior, H; Rubio, TA; Uyemura, JRR; Vilela-Martin, JF; Yugar-Toledo, JC, 2022) |
| "Hypertension is currently one of the greatest global health care challenges." | 5.46 | Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine. ( Barho, C; Gottwald-Hostalek, U; Hildemann, S; Sun, N, 2017) |
| "The dosage of bisoprolol was changed to 3." | 5.36 | [Urinary bladder tuberculosis and bacillus calmette-guérin instillation: reduced efficacy of bisoprolol in hypertension]. ( Drechsler, A; Kirch, W, 2010) |
| "Bisoprolol is an effective antihypertensive drug which reduces significantly the systolic, and diastolic blood pressure, the pulse rate in a recumbent, sitting and standing position." | 5.29 | [Bisoprolol in the treatment of hypertension]. ( Spinar, J; Vítovec, J; Zicha, J, 1993) |
| " Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension (ResHypOT)." | 5.27 | Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized control ( Cestário, EDES; Cosenso-Martin, LN; Fernandes, LAB; Giollo-Júnior, LT; Landim, MIP; Matarucco, CSS; Moreno, H; Tácito, LHB; Uyemura, JRR; Vilela-Martin, JF; Yugar-Toledo, JC, 2018) |
| " Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication." | 5.24 | Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease. ( Fujii, U; Ichihara, E; Ichikawa, H; Kanehiro, A; Kiura, K; Miyahara, N; Morichika, D; Oda, N; Oze, I; Taniguchi, A; Tanimoto, M; Tanimoto, Y, 2017) |
| "This open-label study investigated the long action of bisoprolol compared with metoprolol CR/ZOK for controlling the mean dynamic heart rate (HR) and blood pressure (BP) in patients with mild-to-moderate primary hypertension." | 5.24 | Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. ( Hao, Y; Jiang, Y; Lin, X; Ma, T; Qu, B; Xu, X; Yang, T; Zhou, S, 2017) |
| "This narrative review evaluates recent evidence from four studies which explore the efficacy, safety, and adherence of FDC bisoprolol and amlodipine in patients with hypertension: one observational study; two randomized clinical trials (RCTs); and one indirect comparison analysis." | 5.22 | A growing evidence base for the fixed-dose combination of bisoprolol and amlodipine to manage hypertension. ( Gaciong, Z; Hostalek-Gottwald, U, 2022) |
| "For most adults with resistant hypertension, spironolactone is superior to doxazosin and bisoprolol as an adjunct to triple therapy." | 5.22 | PURLs: Resistant hypertension? Time to consider this fourth-line drug. ( Kaysin, A; Mounsey, A, 2016) |
| " The Genetics of Drug Responsiveness in Essential Hypertension (GENRES) study is a double-blind, placebo-controlled cross-over study where each subject received amlodipine, bisoprolol,hydrochlorothiazide, and losartan, each as a monotherapy, in a randomized order." | 5.20 | Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs. ( Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Donner, KM; Frau, F; Glorioso, N; Glorioso, V; Gong, Y; Gums, JG; Hiltunen, TP; Johnson, JA; Kontula, KK; Ripatti, S; Saarela, J; Salvi, E; Sarin, AP; Turner, ST; Zaninello, R, 2015) |
| "Spironolactone was the most effective add-on drug for the treatment of resistant hypertension." | 5.20 | Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. ( Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, I; McInnes, G; Morant, S; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B, 2015) |
| "The PATHWAY-2 study, funded by the British Heart Foundation, randomised 335 patients with resistant hypertension (already treated according to guidelines) to sequentially receive 12 weeks of spironolactone (25-50 mg), bisoprolol (5-10 mg), doxazosin (4-8 mg modified release) and placebo." | 5.20 | [PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension]. ( Widimský, J, 2015) |
| " A comparative study on the efficacy and safety of bisoprolol and sustained release metoprolol succinate in patients with arterial hypertension (AH), cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) was conducted." | 5.19 | [Efficacy and safety of bisoprololal in hypertensive patients with cardiovascular disease and chronic obstructive pulmonary disease]. ( Chernikov, MV; Derevianchenko, MV; Lopushkova, IuE; Statsenko, ME, 2014) |
| "5 mg hydrochorothiazide + 5 mg amlodipine, 86 patients with resistant hypertension were randomized to the add-on 25 mg spironolactone (MRB group, n = 46) or 5 mg ramipril (RASB group, n = 40) groups for 12 weeks." | 5.19 | Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. ( Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF, 2014) |
| "Aim of the study was to assess effect of monotherapy with nebivolol, bisoprolol, carvedilol for 2 months on sexual function in men with arterial hypertension (AH)." | 5.17 | [Effect of monotherapy with nebivolol, bisoprolol, carvedilol on the state of vegetative nervous system and sexual function in men with arterial hypertension]. ( Mustafaev, II; Nurmamedova, GS, 2013) |
| "222 subjects with hypertension who had received coronary angiography examination were involved in the study, 162 in bisoprolol therapy group (96 men, 59%) and 60 in non-bisoprolol group (39 men, 65%)." | 5.17 | Bisoprolol improved endothelial function and myocardium survival of hypertension with stable angina: a randomized double-blinded trial. ( Dong, M; Lin, ZP; Liu, J, 2013) |
| "TY-0201 (TY) is a new drug absorbed by the transdermal delivery system developed for the treatment of hypertension, which contains the free base of bisoprolol fumarate that is widely used." | 5.17 | Comparison of efficacy and safety between bisoprolol transdermal patch (TY-0201) and bisoprolol fumarate oral formulation in Japanese patients with grade I or II essential hypertension: randomized, double-blind, placebo-controlled study. ( Kuwajima, I; Matsuoka, H; Mitamura, H; Saruta, T; Shimada, K, 2013) |
| "These data suggest that both bisoprolol and losartan are effective agents for the treatment of patients with recently diagnosed ESH stage 1-2 hypertension." | 5.14 | One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study. ( Caradonna, M; Cardillo, M; Di Pasquale, P; La Rocca, G; Licata, G; Mezzero, M; Parrinello, G; Paterna, S; Torres, D; Trapanese, C, 2009) |
| " The aim of this study was to evaluate the influence of antihypertensive drugs (bisoprolol, perindopril or both) in patients suffering from mild to moderate hypertension." | 5.14 | The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines. ( Basiak, M; Buldak, L; Dulawa, A; Madej, A; Okopien, B; Szkrobka, W, 2009) |
| "In the GENRES study, 208 Finnish men aged 35-60 years with moderate hypertension used amlodipine 5 mg, bisoprolol 5 mg, hydrochlorothiazide 25 mg and losartan 50 mg daily, each for 4 weeks as a monotherapy in a double-blind, randomized, placebo-controlled crossover study; that is, each subject received each type of monotherapy in a random order." | 5.13 | Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. ( Donner, K; Hannila-Handelberg, T; Hiltunen, TP; Kontula, K; Miettinen, HE; Paavonen, KJ; Pentikäinen, PJ; Strandberg, T; Suonsyrjä, T; Tikkanen, I; Tilvis, R, 2008) |
| "To investigate the efficacy and safety of bisoprolol/hydrochlorothiazide (Lodoz) in patients with mild and moderate essential hypertension." | 5.12 | [The clinical efficiency and safety of bisoprolol hydrochlorothiazide in patients with mild to moderate essential hypertension]. ( Jiang, H; Ke, YN, 2006) |
| "Amlodipine is an effective treatment for hypertension." | 5.11 | Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. ( Alexander, GJ; Brown, MJ; Byrne, CD; Neal, DA; Wilkinson, IB, 2004) |
| "To compare the efficacy and tolerability of bisoprolol, enalapril and nifedipine retard in the treatment of mild to moderate essential hypertension." | 5.10 | Efficacy of domestic bisoprolol,enalapril and nifedipine retard in mild to moderate hypertension: a randomized double-blind multicenter clinical trial in China. ( Li, M; Liu, G; Shi, X, 2002) |
| "To compare efficacy and safety of atenolol, methoprolol and bisoprolol, as the most usable beta-blockers, in patients with isolated systolic arterial hypertension (ISAH) and concomitant diabetes mellitus (DM) and/or chronic obstructive pulmonary disease (COPD)." | 5.10 | [Efficacy and safety of different beta-blockers in patients with isolated systolic hypertension associated with diabetes mellitus and obstructive pulmonary diseases]. ( Abakumov, IuE; Batutina, AM; Kukes, VG; Mamaev, VI; Ostroumova, OD; Zykova, AA, 2003) |
| "The aim of the present study was to evaluate the antihypertensive efficacy of the highly beta(1)-selective adrenergic antagonist nebivolol in comparison with bisoprolol in the treatment of mild to moderate essential hypertension." | 5.10 | Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). ( Bodnar, J; Czuriga, I; Edes, I; Fulop, T; Kristof, E; Kruzsicz, V; Riecansky, I, 2003) |
| "To compare quality of life with the selective beta1-blocker bisoprolol and the thiazide diuretic bendrofluazide in patients with mild to moderate hypertension." | 5.09 | Impact of antihypertensive treatment on quality of life: comparison between bisoprolol and bendrofluazide. ( de Hoon, JN; Van Bortel, LM; van de Ven, LL; Vanmolkot, FH, 1999) |
| "The aim of this study was to evaluate the long-term effects of administering bisoprolol compared with nitrendipine on the duration of the exercise tolerated by male and female patients, aged 18-65 years, having mild to moderate hypertension and taking regular exercise." | 5.09 | Comparative effects of bisoprolol and nitrendipine on exercise capacity in hypertensive patients with regular physical activity. ( Amoretti, R; Brion, R; Carré, F; Douard, H; Dubanchet, A; Ducardonnet, A; Gauthier, J; Gressin, V; Page, E; Poncelet, P; Verdier, JC, 2000) |
| "25 mg (n = 84) to amlodipine 5 mg (n = 80) in isolated systolic hypertension in patients older than 60 years." | 5.09 | Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. ( Benetos, A; Consoli, S; Dubanchet, A; Safar, M; Safavian, A, 2000) |
| "Bisoprolol, a beta1-selective beta-blocker, was administered to 13 patients with mild to moderate essential hypertension once daily at doses of 5-10 mg for 24 weeks, and its long-term effects on blood pressure and glucose metabolism were investigated." | 5.09 | The effects of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension. ( Hata, T; Miyake, S; Owada, A; Suda, S, 2001) |
| "25 mg of hydrochlorothiazide (HCTZ) given once daily with 5 mg of bisoprolol fumarate can contribute to antihypertensive effectiveness in patients with stage I and stage II (mild to moderate) systemic hypertension; and (2) assess whether this formulation was more effective or possessed a safety advantage over standard monotherapy with bisoprolol or 25 mg of HCTZ." | 5.08 | First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. ( Alemayehu, D; Bryzinski, BS; Burris, JF; Chen, SY; Frishman, WH; Mroczek, WJ; Simon, JS; Weir, MR, 1995) |
| "Quality of life with the selective beta1-blocker bisoprolol and the calcium channel blocker nifedipine as a retard formulation was compared in patients with essential hypertension." | 5.08 | Quality of life comparison between bisoprolol and nifedipine retard in hypertension. ( de Hoon, JN; Van Bortel, LM; van de Ven, LL; Vanmolkot, FH, 1997) |
| "One hundred and six patients in the stage I and stage II of the systemic hypertension (mild to moderate) were given the bisoprolol/hydrochlorothiazide combination once daily and the diastolic and systolic blood pressures were monitored during the 8-week trial." | 5.08 | [Efficacy and tolerance of the bisoprolol/hydrochlorothiazide combination in arterial hypertension]. ( Batlouni, M; Castro, I; Chaves Júnior, Hde C; da Rocha, JC; Feitosa, GS; God, EM; Luna, RL; Maia, LN; Mion, D; Oigman, W; Ortega, KC; Raineri, AM; Ramirez, JA, 1998) |
| "The acute and short-term responses to bisoprolol and to atenolol on systemic and renal hemodynamics and on ambulatory blood pressure (BP) were compared in a randomized double-blind cross-over study including 14 patients with mild to moderate essential hypertension." | 5.07 | Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure. ( Collart, F; Degaute, JP; Leeman, M; Mélot, C; Peeters, L; van de Borne, P; Vandenhoven, G, 1993) |
| " Thirty patients with essential hypertension and left ventricular hypertrophy were studied at baseline after withdrawing all previous treatments and after 6 months of treatment with 5-20 mg of bisoprolol, a new beta-selective agent, to assess its possible action on left ventricular mass." | 5.07 | Effects of bisoprolol on left ventricular hypertrophy in essential hypertension. ( Camacho-Vázquez, C; de Teresa, E; González, M; Tabuenca, MJ, 1994) |
| "In a comparative cross-over trial we examined the influence of the betablocker bisoprolol and the ACE-inhibitor lisinopril on the peripheral blood flow of 2 groups of hypertensive patients with and without concomitant intermittent claudication." | 5.07 | The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. ( Smit, AJ; Van de Ven, LL; Van Leeuwen, JT, 1994) |
| "A total of 512 patients with mild to moderate essential hypertension were randomized to once-daily treatment with bisoprolol (0, 2." | 5.07 | A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. ( Alemayehu, D; Bryzinski, BS; Coulson, LR; DeQuattro, VL; Dukart, G; Frishman, WH; Goldberg, JD; Koury, K; Mroczek, WJ; Vlachakis, ND, 1994) |
| "Atenolol and bisoprolol, two beta-1-selective blockers, were compared in patients with mild and medium severe hypertension." | 5.07 | [Atenolol and bisoprolol in the treatment of mild and moderately severe hypertension]. ( Prásek, J; Soucek, M; Spinarová, L, 1993) |
| "This study used 24-h ambulatory blood pressure (BP) monitoring to investigate the effectiveness of a novel low-dose combination of bisoprolol/hydrochlorothiazide in adult patients with mild to moderate essential hypertension." | 5.07 | A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension. ( Cardenas, P; Lewin, AJ; Lueg, MC; Targum, S, 1993) |
| "The antihypertensive efficacy and compatibility of 5 or 10 mg bisoprolol (Concor) was investigated in patients suffering from essential hypertension (stages I and II according to WHO) in a multicentre, open, non-randomized study." | 5.07 | [The blood pressure lowering effect of bisoprolol, a beta 1-selective receptor blocker--a multicenter study in general practice conditions]. ( Haustein, KO, 1993) |
| "To investigate prospectively the effects of the selective beta 1 adrenoceptor blocker bisoprolol on sexuality of men with hypertension." | 5.07 | Bisoprolol and hypertension: effects on sexual functioning in men. ( Broekman, CP; Haensel, SM; Slob, AK; Van de Ven, LL, 1992) |
| "Blood pressure, heart rate, common carotid and brachial arterial hemodynamics using pulsed Doppler flowmetry and pulse wave velocity determinations were evaluated using a double-blind crossover design versus placebo in 14 patients with sustained essential hypertension treated by the selective beta 1 blocking agent bisoprolol." | 5.07 | Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. ( Asmar, RG; Girerd, XJ; Kerihuel, JC; Safar, ME, 1991) |
| "Forty outpatients (11 men and 29 women) aged between 65 and 85 years (mean age of 68 years) with mild to moderate hypertension [mean systolic/diastolic blood pressure (SBP/DBP) after 2 weeks on placebo of 175/102 mm Hg] were included in a randomized, double-blind, parallel-group study to compare the efficacy and tolerance of 10 mg of bisoprolol once daily (o." | 5.06 | Bisoprolol and nifedipine SR in the treatment of hypertension in the elderly. ( Carretero, J; Garcia, MJ; Garrido, M; Oliván Martinez, J; Pizarro, JL; Rodriguez Botaro, A, 1990) |
| "Twenty-six patients with mild-to-moderate essential hypertension participated in a 6-week outpatient, multicenter, randomized, double-blind, placebo-controlled two-way crossover study to assess the hemodynamic effects of bisoprolol (20 mg QD) at steady state." | 5.06 | Multicenter evaluation of the hemodynamic effects of bisoprolol in patients with mild to moderate hypertension. ( Bryzinski, B; Carr, AA; Desnoyers, M; McKee, B; Nelson, BR; O'Donnell, DM; Prisant, LM; Westcott, RJ; Zinny, MA, 1990) |
| "The aim of the study was to compare the antihypertensive efficacy and safety of a new beta blocker with high beta 1 selectivity, bisoprolol, with captopril in 28 elderly patients, aged over 65 years, with mild-to-moderate essential hypertension (WHO classes I and II)." | 5.06 | A double-blind comparison of bisoprolol and captopril for treatment of essential hypertension in the elderly. ( Alberti, A; Bracchetti, D; Brunelli, A; Cantelli, I; Gradnik, R; Leonardi, G; Orselli, L; Pavesi, PC, 1990) |
| "6 years (32-65 years), with hypertension WHO I-II, were given bisoprolol in doses of 5, 10, and 20 mg." | 5.06 | Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension. ( Frithz, G; Weiner, L, 1986) |
| "Forty-two patients (28 men, 14 women, age range 27-65 years) with newly discovered mild to moderate hypertension were randomly allocated to treatment with either bisoprolol or atenolol for a double-blind comparison of these two beta 1-adrenoceptor blocking drugs." | 5.06 | A comparison of the effects of bisoprolol and atenolol on lipoprotein concentrations and blood pressure. ( Lithell, H; Selinus, I; Vessby, B; Weiner, L, 1986) |
| "The antihypertensive effect and possible adverse effects of bisoprolol were assessed in 96 Japanese patients with mild to moderate hypertension." | 5.06 | Clinical evaluation of bisoprolol in patients with hypertension: interim report. ( Iimura, O; Ikeda, M; Inagaki, Y; Kuramoto, K; Takeda, T, 1986) |
| "The cardioselectivity and hypotensive properties of the beta 1-specific beta-blocker bisoprolol were investigated using a single-dose comparison of 10 and 20 mg bisoprolol, 100 mg atenolol, and placebo in 12 hypertensive asthmatic patients." | 5.06 | The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. ( Chatterjee, SS, 1986) |
| "In a double-blind crossover study, the influence of bisoprolol and placebo was tested in 20 noninsulin-dependent diabetics with concomitant essential hypertension." | 5.06 | Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. ( Disselhoff, G; Janka, HU; Mehnert, H; Ziegler, AG, 1986) |
| "In a multi-center study, 188 patients with mild to moderate essential hypertension were treated with the beta-1 selective beta blocker bisoprolol." | 5.06 | [The 24-hour-effect of bisoprolol on blood pressure at rest and during stress]. ( Bethge, H; Litterer, G; Prager, G; Wagner, G, 1989) |
| "0, range 37-61 years; eight females) with mild essential hypertension (DBP greater than 90 mm Hg on placebo) completed a randomised, double-blind placebo controlled crossover study comparing the hypotensive effects of bisoprolol (10-20 mg) and atenolol (50-100 mg) each taken once daily." | 5.06 | A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. ( Ioannides, C; Johnston, A; Lewis, R; Maclean, D; McDevitt, DG, 1988) |
| "In a 4-week randomized, double-blind study, 87 patients with essential hypertension received either 10 mg bisoprolol (B) or 100 mg metoprolol (M) once daily (o." | 5.06 | Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). ( Bethge, H; Haasis, R, 1987) |
| "Bisoprolol reduces systolic and diastolic blood pressures in patients with hypertension for a 24-hour dosing interval and is associated with beneficial hemodynamic effects in patients with myocardial ischemia." | 4.79 | Bisoprolol: is this just another beta-blocker for hypertension or angina? ( Johns, TE; Lopez, LM, 1995) |
| "This study was conducted on the characteristics of PVC in hypertensive patients with left ventricular hypertrophy and aimed to evaluate the effect of bisoprolol on PVC in Vietnamese patients with hypertension and LVH." | 4.31 | The Effect of Bisoprolol on Premature Ventricular Complex in Vietnamese Patients with Hypertension and Left Ventricular Hypertrophy. ( Bao Nguyen, NN; Huynh, MV; Kim Tran, S; Ngo, TH; Ngoc Huynh, HT; Nguyen, TH; Phuong Nguyen, AT; Vo, CT, 2023) |
| "This study assessed the real-life effectiveness of a single-pill combination (SPC) of bisoprolol/perindopril for controlling blood pressure (BP) and symptoms of angina in patients with hypertension and a history of myocardial infarction (MI)." | 4.31 | Effectiveness and Tolerability of Bisoprolol/Perindopril Single-Pill Combination in Patients with Arterial Hypertension and a History of Myocardial Infarction: The PRIDE Observational Study. ( Burtsev, Y; Kobalava, Z; Kvasnikov, B, 2023) |
| " The prevalence of hypertension in COPD patients ranges from 39-51%, and β-blockers and amlodipine are commonly used drugs for these patients." | 4.31 | Impact of bisoprolol and amlodipine on cardiopulmonary responses and symptoms during exercise in patients with chronic obstructive pulmonary disease. ( Hsieh, PC; Lan, CC; Su, WL; Tzeng, IS; Wu, CW; Wu, YK; Yang, MC, 2023) |
| "The addition of perindopril on top of bisoprolol-based therapy in patients with mild-to-moderate hypertension was associated with significant reductions in BP compared with baseline and with achievement of BP targets in the majority of patients." | 4.12 | Concomitant Treatment of Hypertensive Patients with Bisoprolol and Perindopril in Routine Clinical Practice: A Post Hoc Analysis of the CONFIDENCE II, PROTECT I, and PROTECT III Observational Studies. ( Abeel, M; Constance, C; Gupta, A, 2022) |
| "In the present case, a 58-year old male patient, having ischemic heart disease, controlled hypertension on telmisartan and bisoprolol, experienced hypertensive urgency in a span of two hours of intranasal administration of the paediatric formulation of xylometazoline." | 4.02 | Use of Paediatric Xylometazoline Nasal Drop is not a Child's Play in Hypertensive Patients on Bisoprolol: A Case Report. ( Bhalla, H; Gupta, A; Patel, T, 2021) |
| " This study assessed the effectiveness and tolerability of bisoprolol/perindopril (Bis/Per) single-pill combination (SPC) in Russian patients with hypertension and coronary artery disease (CAD) treated in routine clinical practice." | 4.02 | Effectiveness and Tolerability of the Single-Pill Combination of Bisoprolol and Perindopril in Patients with Arterial Hypertension and Stable Coronary Artery Disease in Daily Clinical Practice: The STYLE Study. ( Boytsov, SA; Burtsev, YP; Karpov, YA; Khomitskaya, YV, 2021) |
| "Bisoprolol can effectively reduce RHR in Asian CAD patients with comorbid hypertension and hence, improve CCCO without affecting their blood pressure." | 3.96 | Resting heart rate control and prognosis in coronary artery disease patients with hypertension previously treated with bisoprolol: a sub-group analysis of the BISO-CAD study. ( Chen, XP; Chen, YD; Fu, GS; Huang, SA; Kim, DS; Kim, TH; Liu, SW; Ma, TR; Pham, VN; Truong, BQ; Yang, XC; Yang, Y, 2020) |
| "Given that it has been reported that type 2 diabetes mellitus may affect the pharmacokinetics of a large number of drugs and that there are still no published population pharmacokinetic (PopPK) analyses in routinely treated patients with hypertension and type 2 diabetes mellitus as comorbid condition, the aim of this study was to determine PK variability of bisoprolol in 70 Serbian patients using the PopPK approach." | 3.96 | Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension. ( Janković, SM; Jovanović, A; Milovanović, JR; Momčilović, S; Nikolić, VN; Pešić, M; Radojković, D, 2020) |
| "The aim: Study of the patterns of structural changes in the left ventricular myocardial capillaries of rats with arterial hypertension with combined pharmacotherapy with Bisoprolol and Thiotriazolinum." | 3.96 | INFLUENCE OF COMBINED PHARMACOTHERAPY ON CARDIO-VASCULAR SYSTEM OF ARTERIAL HYPERTENSION (IN EXPERIMENT). ( Chuhray, SN; Hamalii, VM; Kaminsky, RF; Kovalchuk, OI; Lachtadyr, TV; Lavrynenko, VE; Matkivska, RM; Sokurenko, LM, 2020) |
| "Whether the reduction of heart rate with ivabradine (IVA) could affect sympathetic activation and cardiac innervation in heart failure (HF) remains unknown." | 3.91 | Modulation of Sympathetic Activity and Innervation With Chronic Ivabradine and β-Blocker Therapies: Analysis of Hypertensive Rats With Heart Failure. ( Akiyama, T; Iwanaga, Y; Kakehi, K; Miyazaki, S; Shimizu, S; Sonobe, T; Watanabe, H; Yamamoto, H, 2019) |
| "In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs." | 3.88 | Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. ( Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, IS; McInnes, GT; Morant, SV; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B, 2018) |
| "7 years, 19 men) with uncomplicated hypertension without diabetes were given bisoprolol 5-10 mg." | 3.81 | [The Fixed Combination of Amlodipine and Bisoprolol Eliminates the Effect of -Blockers on Central Pulse Wave in Patients With Arterial Hypertension]. ( Bogomaz, AV; Kobalava, ZD; Kotovskaya, YV, 2015) |
| "To evaluate the efficacy and safety of a fixed-term combination of β-blocker bisoprolol and the calcium antagonist amlodipine in the outpatient treatment of patients with arterial hypertension (AH) and coronary heart disease (CHD)." | 3.80 | [Evaluating the effectiveness of a fixed combination of amlodipine and bisoprolol in ambulatory patients with arterial hypertension and ischemic heart disease]. ( Chesnikova, AI; Kolomatskaia, OE; Safronenko, VA, 2014) |
| " The patient had been treated with amlodipine (Amlor(®)) and a combination of bisoprolol and hydrochlorothiazide (Lodoz(®)) for 5years for essential hypertension." | 3.79 | [Telangiectasia during amlodipine therapy]. ( Dussouil, AS; Gaudy-Marqueste, C; Grob, JJ; Mallet, S; Monestier, S; Richard, MA; Tasei, AM, 2013) |
| " The day before the occurrence of these acute lesions, he self medicated with a drug containing ergotamine and caffeine because of a headache." | 3.79 | [Digital necrosis in hand by uncommon mechanism]. ( Lashak, C; Leroux, MB; Mazzurco, M, 2013) |
| "25 mg of hydrochlorothiazide, the clinical condition, the daily profile of blood pressure, body adrenoreactivity structural and functional parameters of the left ventricle in 28 pregnant women with preeclampsia in the background chronic hypertension (hypertension stage II, 2 nd degree) and 28 pregnant women with preeclampsia and mild to moderate severity in terms of 22-28 weeks of pregnancy." | 3.78 | [Combined low-dose antihypertensive therapy in pregnant women with hypertension and preeclampsia]. ( Manukhin, IB; Markova, EV; Markova, LI; Striuk, RI, 2012) |
| "The aim of this study was to evaluate the effects of antihypertensive therapy (perindopril, bisoprolol and combined therapy) on plasma CRP concentration in 67 subjects with mild or moderate hypertension who have been treatment-naive and otherwise healthy." | 3.78 | Short-term antihypertensive therapy lowers the C-reactive protein level. ( Basiak, M; Bołdys, A; Bułdak, L; Labuzek, K; Madej, A; Okopień, B, 2012) |
| "5/5 mg bisoprolol in 70 patients with essential hypertension." | 3.78 | Hypotensive and heart rate-lowering effects of low-dose bisoprolol determined based on self-measured blood pressure at home. ( Asayama, K; Ikeda, U; Imai, Y; Kikuya, M; Kobayashi, Y; Metoki, H; Obara, T; Ohkubo, T; Satoh, M, 2012) |
| "In a retrospective controlled study, a tumor-protective effect, regarding breast cancer, was determined for the medicines metformin and glitazone (anti-diabetics), bisoprolol, and propranolol (cardioselective β1 adrenoceptor antagonists)." | 3.78 | A retrospective in vitro study of the impact of anti-diabetics and cardioselective pharmaceuticals on breast cancer. ( Briese, V; Richter, C; Richter, DU; Szewczyk, M, 2012) |
| "The investigation has been conducted with the aim of studying association between polymorphic marker G1846A of CYP2D6 gene and efficacy and safety of bisoprolol in 64 pregnant women with chronic stage I and II hypertension." | 3.75 | [Efficacy and safety of bisoprolol in pregnant women with chronic arterial hypertension do not depend on genetic CYP2D6 polymorphism]. ( Brytkova, IaV; Ignat'ev, IV; Kazakov, RE; Sokova, EA; Striuk, RI, 2009) |
| "Measurement of levels of hormones of the pituitary-gonadal system, dopplerography of penile arteries and questioning after Vasiltchenko were carried out in 30 men (age 35-55 years) with I-II degree arterial hypertension who received monotherapy with bisoprolol and nebivolol for 2 months." | 3.74 | [Level of hormones of pituitary-gonadal axis, penile blood flow and sexual function in men with arterial hypertension during monotherapy with bisoprolol and nebivolol]. ( Gumbatov, NB; Mustafaev, II; Nurmamedova, GS, 2007) |
| "Study aim was assessment of clinical efficacy of mono therapy with nifedipine SR/GITS and combination of nifedipine SR/GITS and bisoprolol as well as investigation of functional state of sympathoadrenal system (SAS) in pregnant women with arterial hypertension." | 3.74 | [Clinical efficacy of antihypertensive therapy of pregnant women with arterial hypertension with long acting nifedipine and bisoprolol]. ( Brytkova, IaV; Bukhonkina, IuM; Pavlova, LN; Striuk, RI, 2008) |
| "A case of a 60-year-old male patient, suffering from benign prostatic hyperplasia (BPH), with deterioration of lower urinary tract symptoms (LUTS) during antihypertensive treatment with bisoprolol was presented." | 3.73 | Repeated intensification of lower urinary tract symptoms in the patient with benign prostatic hyperplasia during bisoprolol treatment. ( Chodorowski, Z; Hajduk, A; Sein Anand, J, 2005) |
| "Thirty patients (18 women and 12 men) with metabolic syndrome and mild arterial hypertension took bisoprolol alone in a dose 5-10 mg/day, and fifteen patients received combined therapy (bisoprolol and actovegin) for 12 weeks." | 3.73 | [Primary prophylaxis of cerebrovascular complications in patients with metabolic syndrome]. ( Chazova, IE; Gornostaev, VV; Mychka, VB; Sergienko, VB, 2005) |
| "The efficacy, safety, and pharmacokinetics of bisoprolol were investigated following oral administration once daily for 12 weeks in hyperreninemic patients with dialysis-refractory hypertension." | 3.70 | Pharmacokinetics of bisoprolol and its effect on dialysis refractory hypertension. ( Hiroshige, K; Iwamoto, M; Kanegae, K; Nakashima, Y; Ohta, T; Ohtani, A; Suda, T, 1999) |
| "Long-term efficacy and safety of the beta1-selective adrenoceptor-blocking agent bisoprolol was investigated in 164 patients with mild to moderate essential hypertension who had already been treated successfully with bisoprolol once daily for 1 year in preceding studies." | 3.68 | Three years of experience with bisoprolol in the treatment of mild to moderate hypertension. ( Buchner-Möll, D; Giesecke, HG, 1990) |
| "In an open multicenter study, 2,012 patients with mild to moderate essential hypertension were treated for 8 weeks with the beta1-selective blocker bisoprolol." | 3.68 | Age dependence of therapy result and risk in the treatment of arterial hypertension? ( Höffler, D; Morgenstern, HO, 1990) |
| "The authors administered to 10 patients with mild hypertension a single dose of 10 mg bisoprolol (Concor-Merck) during bioimpedance control of changes of the cardiac index and peripheral vascular resistance after an interval of 3 and 24 hours following administration of the drug." | 3.68 | [The effect of a single dose of Bisoprolol on changes in blood pressure and hemodynamic indicators in patients with mild hypertension]. ( Marek, D; Oral, I; Vareka, I, 1992) |
| "The authors administered to 10 patients with mild hypertension a single dose of 10 mg bisoprolol (CONCOR-Merck) during bioimpedance control of changes of the cardiac index and peripheral vascular resistance during an isometric load after an interval of 3 and 24 hours following administration of the drug." | 3.68 | [The effect of a single dose of Bisoprolol on changes in blood pressure and hemodymic indicators in patients with mild hypertension during loading]. ( Marek, D; Oral, I; Vareka, I, 1992) |
| "The effects of single doses of 10, 20, and 40 mg of bisoprolol on left ventricular performance were assessed by left ventricular systolic time interval measurements, echocardiographic measurements, and exercise stress tests in patients with mild to moderate arterial hypertension." | 3.67 | Noninvasive assessment of left ventricular performance after administration of bisoprolol. ( Burrieza, OH; Esper, RC; Esper, RJ; Menna, J, 1986) |
| "In 242 patients with hypertension and/or angina pectoris, a new cardioselective betablocker without ISA, bisoprolol (Concor), was tested." | 3.67 | [A new beta 1-receptor blocker in the therapy of essential hypertension and angina pectoris]. ( Burkart, F; Stamm, G; Witassek, F, 1989) |
| "Fifty patients with essential hypertension WHO Grades I-II have been treated for 3 months with bisoprolol, a new selective beta blocker, in doses up to 40 mg once daily." | 3.67 | Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. ( Frithz, G; Weiner, L, 1987) |
| "The Quadruple UltrA-low-dose tReaTment for hypErTension (QUARTET) double-blind, active-controlled, randomized clinical trial will examine whether ultra-low-dose quadruple combination therapy is more effective than guideline-recommended standard care in lowering blood pressure." | 3.01 | Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. ( Atkins, ER; Billot, L; Chalmers, J; Chow, CK; Hay, P; Hillis, GS; Neal, B; Nelson, M; Patel, A; Reid, CM; Rodgers, A; Schlaich, M; Usherwood, T; Webster, R, 2021) |
| "The aim of our study was to estimate clearance of bisoprolol and reveal the factors that could influence its pharmacokinetic (PK) variability in hypertensive patients on hemodialysis, using the population PK analysis." | 2.82 | Population Pharmacokinetics of Bisoprolol in Hemodialysis Patients with Hypertension. ( Andric, BR; Dimitrijevic, ZM; Jankovic, SM; Jevtovic-Stoimenov, T; Milovanovic, JR; Nikolic, VN; Petrovic, DS; Sokolovic, MJ; Zivanovic, S, 2016) |
| "Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months." | 2.78 | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. ( Dobrokhod, AS; Kushnir, SM; Radchenko, GD; Sirenko, YM; Torbas, OO, 2013) |
| "Hypertensive left ventricular hypertrophy (HTN LVH) is associated with almost threefold increased risk of ventricular tachycardia (VT)/ventricular fibrillation (VF)." | 2.72 | Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk. ( Koracevic, G; Lovic, D; Sakac, D; Stojanovic, M; Zdravkovic, M, 2021) |
| "01), although the once-daily dosing of enalapril and the maximum dose of 20 mg might not have been optimal for this agent." | 2.68 | Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. ( Adegbile, IA; Alemayehu, D; Carr, AA; Lefkowitz, MP; Papademetriou, V; Prisant, LM; Weber, MA; Weir, MR, 1995) |
| " A once-daily dosing schedule was evaluated by comparing bisoprolol's antihypertensive effectivness and safety at 24 h postdose and 3 h postdose, the latter time intended to correspond to peak effectiveness." | 2.67 | Bisoprolol, a once-a-day beta-blocking agent for patients with mild to moderate hypertension. ( Alemayehu, D; Blumenthal, JB; Bryzinski, BS; Davidov, ME; Koury, KJ; Simon, JS; Singh, SP; Vlachakis, ND, 1994) |
| " Office BPs were recorded at the end of the 24-hour dosing interval (trough)." | 2.67 | Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. ( Fagan, TC; Kaplan, NM; Kazempour, MK; Lefkowitz, MP; Neutel, JM; Papademetriou, V; Ram, CV; Smith, DH; Weber, MA, 1993) |
| "Bisoprolol and atenolol were similar in the black (10 +/- 5/9 +/- 3 mm Hg [n = 22] and 10 +/- 6/6 +/- 3 mm Hg [n = 13], respectively) and young (15 +/- 1/11 +/- 1 mm Hg [n = 84] and 16 +/- 2/10 +/- 1 mm Hg [n = 66], respectively) groups." | 2.67 | Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group. ( Kazempour, MK; Lefkowitz, MP; Neutel, JM; Ram, CV; Smith, DH; Weber, MA, 1993) |
| "Bisoprolol and enalapril were similarly effective in lowering blood pressure (BP) in the office and during 24-h monitoring and in reducing the left ventricular mass index in hypertensive patients." | 2.67 | Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. ( Dallocchio, M; Gosse, P; Herrero, G; Roudaut, R, 1990) |
| " Forty-six outpatients suffering from mild to moderate essential hypertension [diastolic blood pressure (DBP) ranging between 95 and 120 mm Hg] were randomly given either 10 mg of bisoprolol or 400 mg of acebutolol once a day for 8 weeks; this dosage was doubled after 4 weeks if DBP was still above 90 mm Hg." | 2.67 | Effect of bisoprolol and acebutolol on resting blood pressure and on exercise blood pressure profile in hypertensive patients: a comparative, single-blind study. ( Bouvier, JM; Herrero, G; Rabot, D, 1990) |
| "Bisoprolol was significantly more effective than nitrendipine, which did not induce a significant reduction in the ambulatory night-time recordings." | 2.67 | Comparison of casual, ambulatory and self-measured blood pressure in a study of nitrendipine vs bisoprolol. ( Bättig, B; Buddeberg, C; Jeck, T; Mengden, T; Schubert, M; Vetter, W; Weisser, B, 1992) |
| "of bisoprolol was added to the maximal dose of nitrendipine (20 mg o." | 2.67 | Nitrendipine in the therapeutic management of elderly hypertensive patients: results of a multicenter trial. Andalousian Hypertension Group. ( Aranda, P; Fernandez, JA; Lopez de Novales, E; Lopez, S, 1992) |
| " The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs." | 2.67 | A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ( Dixon, MS; Sheridan, DJ; Thomas, P, 1990) |
| "The technique of population pharmacokinetic analysis was employed to study the variability in the dose concentration relationship of bisoprolol during its clinical development." | 2.66 | Population pharmacokinetic analysis of bisoprolol. ( Grevel, J; Thomas, P; Whiting, B, 1989) |
| "Bisoprolol is a new beta 1-selective beta-blocking agent with a plasma half-time of 10-12 h and without partial agonist properties." | 2.66 | Antihypertensive effects of bisoprolol during once daily administration in patients with essential hypertension. A dose-ranging study with parallel groups. ( Frithz, G; Weiner, L, 1986) |
| " Bisoprolol is effective, well-tolerated and safe in the treatment of hypertension." | 2.66 | Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study. ( Frithz, G; Hosie, J; Lithell, H; Selinus, I; Weiner, L, 1987) |
| "Type 2 diabetes is becoming very common and is closely linked to physical inactivity and obesity." | 2.41 | Beta-blockers and diabetes: the bad guys come good. ( Cruickshank, JM, 2002) |
| "Bisoprolol is a beta 1-adrenoceptor antagonist with no partial agonist (intrinsic sympathomimetic) activity or membrane stabilising (local anaesthetic) activity." | 2.37 | Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. ( Lancaster, SG; Sorkin, EM, 1988) |
| "Emphysema was induced in male Wistar rats by four weekly pulmonary instillations of elastase (4UI) and exacerbation by a single dose of lipopolysaccharides (LPS)." | 1.91 | Elevated Blood Pressure Occurs without Endothelial Dysfunction in a Rat Model of Pulmonary Emphysema. ( Alburquerque, L; Bideaux, P; Bourdin, A; Cazorla, O; Charrabi, A; Desplanche, E; Gouzi, F; Grillet, PE; Virsolvy, A; Wynands, Q, 2023) |
| "Patients with bilateral primary aldosteronism (PA) generally are treated with antihypertensive drugs, but optimal treatment for patients with complications due to refractory hypertension has not been established." | 1.91 | Unilateral adrenalectomy for a drug-resistant bilateral primary aldosteronism with heart failure: pathophysiology and surgical indication. ( Akaihata, H; Hata, J; Honda-Takinami, R; Hoshi, S; Kataoka, M; Kojima, Y; Matsuoka, K; Ogawa, S; Onagi, A; Sato, Y; Tanji, R, 2023) |
| "Bisoprolol was shown to effectively reduce CASP and this effect was directly proportional to the reduction in Br-SBP and of a similar magnitude." | 1.72 | Effect of bisoprolol on central aortic systolic pressure in Chinese hypertensive patients after the initial dose and long-term treatment. ( Tomlinson, B; Zeng, W, 2022) |
| "However, orthostatic hypotension (OH) is sometimes caused by BBs." | 1.56 | Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension. ( Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T; Sano, T, 2020) |
| "Simultaneous occurrence of transient global amnesia and Takotsubo syndrome has been only rarely reported." | 1.51 | Simultaneous transient global amnesia and Takotsubo syndrome after death of a relative: a case report. ( Finsterer, J; Stollberger, C, 2019) |
| "Hypertension is currently one of the greatest global health care challenges." | 1.46 | Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine. ( Barho, C; Gottwald-Hostalek, U; Hildemann, S; Sun, N, 2017) |
| "Treatment with amlodipine, candesartan, or indapamide did not significantly affect plasma visfatin levels." | 1.43 | Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. ( Piecha, G; Skoczylas, A; Więcek, A, 2016) |
| "The dosage of bisoprolol was changed to 3." | 1.36 | [Urinary bladder tuberculosis and bacillus calmette-guérin instillation: reduced efficacy of bisoprolol in hypertension]. ( Drechsler, A; Kirch, W, 2010) |
| "Bisoprolol was more potent against isoprenaline, T-0509 and procaterol on the SHR than WKY rat right atrium." | 1.31 | Functional beta1- and beta2-adrenoceptors in the left and right atrium of pre-hypertensive rats. ( Doggrell, SA, 2002) |
| "Indications for treatment were hypertension (75%), coronary artery disease with (12%) or without (3%) hypertension, or unknown (10%)." | 1.30 | Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics. ( Danser, AH; Hense, HW; Holmer, SR; Mayer, B; Riegger, GA; Schunkert, H, 1998) |
| "In bisoprolol-treated animals, systolic blood pressure did not change and was even significantly higher than in controls." | 1.29 | Life survival and cardiovascular structures following selective beta-blockade in spontaneously hypertensive rats. ( Benetos, A; Levy, BI; Poitevin, P; Prost, PL; Safar, ME, 1994) |
| "Bisoprolol is an effective antihypertensive drug which reduces significantly the systolic, and diastolic blood pressure, the pulse rate in a recumbent, sitting and standing position." | 1.29 | [Bisoprolol in the treatment of hypertension]. ( Spinar, J; Vítovec, J; Zicha, J, 1993) |
| "Bisoprolol was also able to reduce microalbuminuria during the 24 h and in the rest period preceding the test, but the same percent increase was observed during tests." | 1.28 | Cardiovascular reactivity to and renal impact of stress and exercise: effects of bisoprolol. ( Bernard, N; Fauvel, JP; Hadj-Aissa, A; Laville, M; Pozet, N; Sassard, J; Zech, P, 1990) |
| "Bisoprolol was devoid of affinity for autonomic receptors other than beta-adrenoceptors or for autacoid receptors." | 1.27 | High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol. ( Becker, KH; Bergmann, R; Enenkel, HJ; Haeusler, G; Klockow, M; Minck, KO; Schelling, P; Schliep, HJ; Schmitges, CJ; Schulze, E, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (9.77) | 18.7374 |
| 1990's | 76 (29.69) | 18.2507 |
| 2000's | 47 (18.36) | 29.6817 |
| 2010's | 80 (31.25) | 24.3611 |
| 2020's | 28 (10.94) | 2.80 |
| Authors | Studies |
|---|---|
| Chow, CK | 2 |
| Atkins, ER | 2 |
| Hillis, GS | 2 |
| Nelson, MR | 1 |
| Reid, CM | 2 |
| Schlaich, MP | 1 |
| Hay, P | 2 |
| Rogers, K | 1 |
| Billot, L | 2 |
| Burke, M | 1 |
| Chalmers, J | 2 |
| Neal, B | 2 |
| Patel, A | 2 |
| Usherwood, T | 2 |
| Webster, R | 2 |
| Rodgers, A | 2 |
| Dudinskaya, E | 1 |
| Tkacheva, O | 1 |
| Bazaeva, E | 1 |
| Matchekhina, L | 1 |
| Eruslanova, K | 1 |
| Sharashkina, N | 1 |
| Kotovskaya, Y | 1 |
| Larina, V | 1 |
| Zeng, W | 1 |
| Tomlinson, B | 1 |
| Abeel, M | 1 |
| Gupta, A | 2 |
| Constance, C | 1 |
| Youssef, AM | 1 |
| Elghoneimy, HA | 1 |
| Helmy, MW | 1 |
| Abdelazeem, AM | 1 |
| El-Khodary, NM | 1 |
| Foch, C | 1 |
| Feifel, J | 1 |
| Gottwald-Hostalek, U | 3 |
| Hostalek-Gottwald, U | 1 |
| Gaciong, Z | 1 |
| Gavrilova, A | 1 |
| Zolovs, M | 1 |
| Latkovskis, G | 1 |
| Urtāne, I | 1 |
| Cestario, EDES | 2 |
| Vilela-Martin, JF | 2 |
| Cosenso-Martin, LN | 2 |
| Rubio, TA | 1 |
| Uyemura, JRR | 2 |
| da Silva Lopes, V | 1 |
| Fernandes, LAB | 2 |
| Bonalume Tacito, LH | 1 |
| Moreno Junior, H | 1 |
| Yugar-Toledo, JC | 2 |
| Kim Tran, S | 1 |
| Ngo, TH | 1 |
| Phuong Nguyen, AT | 1 |
| Ngoc Huynh, HT | 1 |
| Vo, CT | 1 |
| Bao Nguyen, NN | 1 |
| Nguyen, TH | 1 |
| Huynh, MV | 1 |
| Hohl, M | 1 |
| Lauder, L | 1 |
| Sevimli, Ö | 1 |
| Tokcan, M | 1 |
| Wagmann, L | 1 |
| Götzinger, F | 1 |
| Schneider, C | 1 |
| Hübner, U | 1 |
| Lehnert, U | 1 |
| Meyer, MR | 1 |
| Böhm, M | 1 |
| Mahfoud, F | 1 |
| Kobalava, Z | 1 |
| Kvasnikov, B | 1 |
| Burtsev, Y | 1 |
| Lan, CC | 1 |
| Hsieh, PC | 1 |
| Tzeng, IS | 1 |
| Yang, MC | 1 |
| Wu, CW | 1 |
| Su, WL | 1 |
| Wu, YK | 1 |
| Desplanche, E | 1 |
| Grillet, PE | 1 |
| Wynands, Q | 1 |
| Bideaux, P | 1 |
| Alburquerque, L | 1 |
| Charrabi, A | 1 |
| Bourdin, A | 1 |
| Cazorla, O | 1 |
| Gouzi, F | 1 |
| Virsolvy, A | 1 |
| Hoshi, S | 1 |
| Onagi, A | 1 |
| Tanji, R | 1 |
| Honda-Takinami, R | 1 |
| Matsuoka, K | 1 |
| Hata, J | 1 |
| Sato, Y | 1 |
| Akaihata, H | 1 |
| Kataoka, M | 1 |
| Ogawa, S | 1 |
| Kojima, Y | 1 |
| Singh, S | 1 |
| Warren, HR | 1 |
| Hiltunen, TP | 7 |
| McDonough, CW | 1 |
| El Rouby, N | 1 |
| Salvi, E | 2 |
| Wang, Z | 1 |
| Garofalidou, T | 1 |
| Fyhrquist, F | 1 |
| Kontula, KK | 3 |
| Glorioso, V | 2 |
| Zaninello, R | 2 |
| Glorioso, N | 2 |
| Pepine, CJ | 1 |
| Munroe, PB | 1 |
| Turner, ST | 2 |
| Chapman, AB | 2 |
| Boerwinkle, E | 2 |
| Johnson, JA | 2 |
| Gong, Y | 2 |
| Cooper-DeHoff, RM | 2 |
| Kayser, A | 2 |
| Beck, E | 1 |
| Hoeltzenbein, M | 2 |
| Zinke, S | 2 |
| Meister, R | 2 |
| Weber-Schoendorfer, C | 2 |
| Schaefer, C | 2 |
| Piani, F | 1 |
| Landolfo, M | 1 |
| Fiorini, G | 1 |
| D'Addato, S | 1 |
| Mancia, G | 1 |
| Borghi, C | 2 |
| Kuzmin, OB | 1 |
| Buchneva, NN | 1 |
| Zhezha, VV | 1 |
| Serdyuk, SV | 1 |
| Kiuchi, S | 1 |
| Hisatake, S | 1 |
| Kabuki, T | 1 |
| Oka, T | 1 |
| Dobashi, S | 1 |
| Fujii, T | 1 |
| Sano, T | 1 |
| Ikeda, T | 1 |
| Doumas, M | 2 |
| Imprialos, KP | 1 |
| Kallistratos, MS | 1 |
| Manolis, AJ | 1 |
| Sánez Tähtisalo, H | 1 |
| Kenttä, T | 1 |
| Junttila, J | 1 |
| Oikarinen, L | 2 |
| Virolainen, J | 3 |
| Porthan, K | 2 |
| Chen, YD | 1 |
| Yang, XC | 1 |
| Pham, VN | 1 |
| Huang, SA | 1 |
| Fu, GS | 1 |
| Chen, XP | 1 |
| Truong, BQ | 1 |
| Yang, Y | 1 |
| Liu, SW | 1 |
| Ma, TR | 1 |
| Kim, DS | 1 |
| Kim, TH | 1 |
| Momčilović, S | 1 |
| Jovanović, A | 1 |
| Radojković, D | 1 |
| Nikolić, VN | 2 |
| Janković, SM | 2 |
| Pešić, M | 1 |
| Milovanović, JR | 2 |
| Nelson, M | 1 |
| Schlaich, M | 1 |
| Chuhray, SN | 1 |
| Lavrynenko, VE | 1 |
| Matkivska, RM | 1 |
| Lachtadyr, TV | 1 |
| Hamalii, VM | 1 |
| Kaminsky, RF | 1 |
| Kovalchuk, OI | 1 |
| Sokurenko, LM | 1 |
| Bhalla, H | 1 |
| Patel, T | 1 |
| Koracevic, G | 1 |
| Stojanovic, M | 1 |
| Lovic, D | 1 |
| Zdravkovic, M | 1 |
| Sakac, D | 1 |
| Boytsov, SA | 1 |
| Burtsev, YP | 1 |
| Khomitskaya, YV | 1 |
| Karpov, YA | 1 |
| AlHabeeb, W | 1 |
| Mrabeti, S | 1 |
| Abdelsalam, AAI | 1 |
| Turgeon, R | 1 |
| Garrison, S | 1 |
| Allan, GM | 1 |
| Taniguchi, A | 1 |
| Miyahara, N | 1 |
| Oda, N | 2 |
| Morichika, D | 1 |
| Ichihara, E | 1 |
| Oze, I | 1 |
| Tanimoto, Y | 1 |
| Ichikawa, H | 1 |
| Fujii, U | 1 |
| Tanimoto, M | 1 |
| Kanehiro, A | 1 |
| Kiura, K | 1 |
| Giollo-Júnior, LT | 1 |
| Matarucco, CSS | 1 |
| Landim, MIP | 1 |
| Tácito, LHB | 1 |
| Moreno, H | 1 |
| Sairaku, A | 1 |
| Nakano, Y | 1 |
| Shiode, N | 1 |
| Suenari, K | 1 |
| Ono, K | 1 |
| Kihara, Y | 1 |
| de la Sierra, A | 1 |
| Armario, P | 1 |
| Oliveras, A | 1 |
| Banegas, JR | 1 |
| Gorostidi, M | 1 |
| Vinyoles, E | 1 |
| de la Cruz, JJ | 1 |
| Segura, J | 1 |
| Ruilope, LM | 1 |
| Williams, B | 3 |
| MacDonald, TM | 4 |
| Morant, SV | 2 |
| Webb, DJ | 2 |
| Sever, P | 2 |
| McInnes, GT | 1 |
| Ford, I | 2 |
| Cruickshank, JK | 2 |
| Caulfield, MJ | 2 |
| Padmanabhan, S | 2 |
| Mackenzie, IS | 1 |
| Salsbury, J | 2 |
| Brown, MJ | 5 |
| Madej, A | 4 |
| Dąbek, J | 2 |
| Majewski, M | 1 |
| Szuta, J | 1 |
| Fietz, AK | 1 |
| Gilyarevsky, SR | 1 |
| Golshmid, MV | 1 |
| Kuzmina, IM | 1 |
| Finsterer, J | 1 |
| Stollberger, C | 1 |
| Kakehi, K | 1 |
| Iwanaga, Y | 1 |
| Watanabe, H | 1 |
| Sonobe, T | 1 |
| Akiyama, T | 1 |
| Shimizu, S | 1 |
| Yamamoto, H | 1 |
| Miyazaki, S | 1 |
| Kishi, T | 1 |
| Fujii, E | 1 |
| Hantson, P | 1 |
| Dupre Z, T | 1 |
| Di Fazio, V | 1 |
| Dussouil, AS | 1 |
| Gaudy-Marqueste, C | 1 |
| Tasei, AM | 1 |
| Monestier, S | 1 |
| Mallet, S | 1 |
| Grob, JJ | 1 |
| Richard, MA | 1 |
| Nurmamedova, GS | 3 |
| Mustafaev, II | 3 |
| Lin, ZP | 1 |
| Dong, M | 1 |
| Liu, J | 1 |
| Bradley, A | 1 |
| Sheridan, P | 1 |
| M'Buyamba-Kabangu, JR | 3 |
| Anisiuba, BC | 3 |
| Ndiaye, MB | 3 |
| Lemogoum, D | 3 |
| Jacobs, L | 1 |
| Ijoma, CK | 3 |
| Thijs, L | 3 |
| Boombhi, HJ | 3 |
| Kaptue, J | 3 |
| Kolo, PM | 3 |
| Mipinda, JB | 2 |
| Osakwe, CE | 1 |
| Odili, A | 1 |
| Ezeala-Adikaibe, B | 2 |
| Kingue, S | 3 |
| Omotoso, BA | 3 |
| Ba, SA | 3 |
| Ulasi, II | 3 |
| Staessen, JA | 3 |
| Puzyrenko, AM | 1 |
| Chekman, IS | 1 |
| Kuftyreva, TP | 1 |
| Horchakova, NO | 1 |
| Leroux, MB | 1 |
| Lashak, C | 1 |
| Mazzurco, M | 1 |
| Zhou, WJ | 1 |
| Wang, RY | 1 |
| Li, Y | 1 |
| Chen, DR | 1 |
| Chen, EZ | 1 |
| Zhu, DL | 1 |
| Gao, PJ | 1 |
| Piekarska, A | 1 |
| Niklas, A | 1 |
| Stryczyński, L | 1 |
| Juszkat, R | 1 |
| Tykarski, A | 1 |
| Radchenko, GD | 1 |
| Sirenko, YM | 1 |
| Kushnir, SM | 1 |
| Torbas, OO | 1 |
| Dobrokhod, AS | 1 |
| Matsuoka, H | 1 |
| Kuwajima, I | 1 |
| Shimada, K | 1 |
| Mitamura, H | 1 |
| Saruta, T | 1 |
| Statsenko, ME | 1 |
| Derevianchenko, MV | 1 |
| Chernikov, MV | 1 |
| Lopushkova, IuE | 1 |
| Azizi, M | 2 |
| Perdrix, L | 1 |
| Bobrie, G | 2 |
| Frank, M | 2 |
| Chatellier, G | 2 |
| Ménard, J | 2 |
| Plouin, PF | 2 |
| Navarro Suay, R | 1 |
| de Tena Gómez, MD | 1 |
| García Aroca, MÁ | 1 |
| López Soberón, E | 1 |
| Eguchi, K | 1 |
| Hoshide, S | 1 |
| Kario, K | 1 |
| Donner, KM | 2 |
| Sarin, AP | 1 |
| Saarela, J | 1 |
| Ripatti, S | 1 |
| Gums, JG | 1 |
| Frau, F | 1 |
| Chesnikova, AI | 1 |
| Safronenko, VA | 1 |
| Kolomatskaia, OE | 1 |
| Czarnecka, D | 1 |
| Koch, EM | 1 |
| Zaremba, IeKh | 1 |
| Zaremba-Fedchyshyn, OV | 1 |
| Virna, MM | 1 |
| Bula, MS | 1 |
| Zaremba, OV | 1 |
| Aparicio, LS | 1 |
| Alfie, J | 1 |
| Barochiner, J | 1 |
| Cuffaro, PE | 1 |
| Giunta, DH | 1 |
| Elizondo, CM | 1 |
| Tortella, JJ | 1 |
| Morales, MS | 1 |
| Rada, MA | 1 |
| Waisman, GD | 1 |
| Hara, T | 1 |
| Yagi, S | 2 |
| Akaike, M | 1 |
| Sata, M | 1 |
| Siles, N | 1 |
| Baranchuk, A | 1 |
| Garro, HA | 1 |
| Chiale, PA | 1 |
| Sternlicht, H | 1 |
| Bakris, GL | 1 |
| Morant, S | 1 |
| McInnes, G | 1 |
| Mackenzie, I | 1 |
| Huynh, K | 1 |
| Tariovskaya, EI | 1 |
| Skibitskiy, VV | 1 |
| Malchikova, SV | 1 |
| Fendrikova, AV | 1 |
| Skibitskiy, AV | 1 |
| Sirotenko, DV | 1 |
| Dimitrijevic, ZM | 1 |
| Sokolovic, MJ | 1 |
| Andric, BR | 1 |
| Petrovic, DS | 1 |
| Jevtovic-Stoimenov, T | 1 |
| Zivanovic, S | 1 |
| Widimský, J | 1 |
| Rosenberg, M | 1 |
| Stephens, E | 1 |
| Divisón Garrote, JA | 1 |
| Escobar Cervantes, C | 1 |
| Boutari, C | 1 |
| Stavropoulos, K | 1 |
| Imprialos, K | 1 |
| Karagiannis, A | 1 |
| Gkaliagkousi, E | 1 |
| Gavriilaki, E | 1 |
| Triantafyllou, A | 1 |
| Douma, S | 1 |
| Dale, A | 1 |
| Hartley, P | 1 |
| Goldacre, B | 1 |
| Skoczylas, A | 1 |
| Piecha, G | 1 |
| Więcek, A | 1 |
| Goupil, R | 1 |
| Dupuis, D | 1 |
| Troyanov, S | 1 |
| Madore, F | 1 |
| Agharazii, M | 1 |
| Kaysin, A | 1 |
| Mounsey, A | 1 |
| Fi, Z | 1 |
| Szentes, V | 1 |
| Yang, T | 1 |
| Jiang, Y | 1 |
| Hao, Y | 1 |
| Zhou, S | 1 |
| Xu, X | 1 |
| Qu, B | 1 |
| Lin, X | 1 |
| Ma, T | 1 |
| Talotta, R | 1 |
| Atzeni, F | 1 |
| Batticciotto, A | 1 |
| Ventura, D | 1 |
| Sarzi-Puttini, P | 1 |
| Sun, N | 2 |
| Barho, C | 1 |
| Hildemann, S | 1 |
| Cohen, BJ | 1 |
| Ostroumova, OD | 2 |
| Pervichko, EI | 1 |
| Zinchenko, YP | 1 |
| Kobalava, ZD | 1 |
| Kotovskaya, YV | 1 |
| Bogomaz, AV | 1 |
| Gridina, SA | 1 |
| Povetkin, SV | 1 |
| Viitasalo, M | 1 |
| Vaananen, H | 1 |
| Suonsyrja, T | 4 |
| Hannila-Handelberg, T | 4 |
| Nieminen, MS | 1 |
| Toivonen, L | 1 |
| Kontula, K | 4 |
| Solà, R | 1 |
| Boj, M | 1 |
| Hernandez-Flix, S | 1 |
| Camprubí, M | 1 |
| Cicero, AF | 1 |
| Veronesi, M | 1 |
| Prandin, MG | 1 |
| Di Gregori, V | 1 |
| Ambrosioni, E | 1 |
| Brytkova, IaV | 2 |
| Ignat'ev, IV | 1 |
| Kazakov, RE | 1 |
| Sokova, EA | 1 |
| Striuk, RI | 3 |
| Parrinello, G | 1 |
| Paterna, S | 1 |
| Torres, D | 1 |
| Di Pasquale, P | 1 |
| Mezzero, M | 1 |
| La Rocca, G | 1 |
| Cardillo, M | 1 |
| Trapanese, C | 1 |
| Caradonna, M | 1 |
| Licata, G | 1 |
| Bakovic, D | 1 |
| Pivac, N | 1 |
| Eterovic, D | 1 |
| Palada, I | 1 |
| Valic, Z | 1 |
| Paukovic-Sekulic, B | 1 |
| Dujic, Z | 1 |
| Buldak, L | 1 |
| Basiak, M | 3 |
| Szkrobka, W | 1 |
| Dulawa, A | 1 |
| Okopien, B | 3 |
| Osadchiĭ, KK | 1 |
| Chen, WQ | 1 |
| Cai, H | 1 |
| Zhang, C | 1 |
| Ji, XP | 1 |
| Zhang, Y | 1 |
| Suzuki, J | 1 |
| Ogawa, M | 1 |
| Tamura, N | 1 |
| Maejima, Y | 1 |
| Takayama, K | 1 |
| Maemura, K | 1 |
| Honda, K | 1 |
| Hirata, Y | 1 |
| Nagai, R | 1 |
| Isobe, M | 1 |
| O-Uchi, J | 1 |
| Lopes, CM | 1 |
| Gierek-Ciaciura, S | 1 |
| Haberka, M | 1 |
| Lekston-Madej, J | 1 |
| Domańska, O | 1 |
| Drechsler, A | 1 |
| Kirch, W | 1 |
| Odili, AN | 2 |
| Richart, T | 1 |
| Kamdem, MK | 1 |
| Aderibigbe, A | 1 |
| Rajzer, M | 1 |
| Wojciechowska, W | 1 |
| Kawecka-Jaszcz, K | 1 |
| Undas, A | 1 |
| Baulmann, J | 1 |
| Schunkert, H | 2 |
| Manukhin, IB | 1 |
| Markova, EV | 1 |
| Markova, LI | 1 |
| Bołdys, A | 1 |
| Bułdak, L | 1 |
| Labuzek, K | 1 |
| Satoh, M | 1 |
| Obara, T | 1 |
| Ikeda, U | 1 |
| Kobayashi, Y | 1 |
| Metoki, H | 1 |
| Asayama, K | 1 |
| Kikuya, M | 1 |
| Ohkubo, T | 1 |
| Imai, Y | 1 |
| Szewczyk, M | 1 |
| Richter, C | 1 |
| Briese, V | 1 |
| Richter, DU | 1 |
| Kamdem, MM | 1 |
| Shu, EN | 1 |
| Peyrard, S | 1 |
| Boutouyrie, P | 1 |
| Laurent, S | 1 |
| Mamedov, MN | 1 |
| Minushkina, LO | 1 |
| Afanas'ev, IuI | 1 |
| Storozhenko, SIu | 1 |
| Grigorova, SIu | 1 |
| Liu, G | 1 |
| Li, M | 1 |
| Shi, X | 1 |
| Doggrell, SA | 2 |
| Mounier-Véhier, C | 2 |
| Clerson, P | 2 |
| Laude, D | 1 |
| Elkohen, M | 2 |
| Poncelet, P | 2 |
| Goullard, L | 1 |
| Baláti, B | 1 |
| Phung, H | 1 |
| Pousset, F | 1 |
| Isnard, R | 1 |
| Boisvieux, A | 1 |
| Carayon, A | 1 |
| Komajda, M | 1 |
| Lechat, P | 2 |
| Cruickshank, JM | 1 |
| Kukes, VG | 1 |
| Mamaev, VI | 1 |
| Batutina, AM | 1 |
| Abakumov, IuE | 1 |
| Zykova, AA | 1 |
| Minami, N | 1 |
| Yoshikawa, T | 1 |
| Kataoka, H | 1 |
| Mori, N | 1 |
| Nagasaka, M | 1 |
| Kurosawa, H | 1 |
| Kanazawa, M | 1 |
| Kohzuki, M | 1 |
| Czuriga, I | 1 |
| Riecansky, I | 1 |
| Bodnar, J | 1 |
| Fulop, T | 1 |
| Kruzsicz, V | 1 |
| Kristof, E | 1 |
| Edes, I | 1 |
| Patel, MR | 1 |
| Gattis, W | 1 |
| Okajima, K | 1 |
| Harada, N | 1 |
| Uchiba, M | 1 |
| Isobe, H | 1 |
| Neal, DA | 1 |
| Wilkinson, IB | 1 |
| Byrne, CD | 1 |
| Alexander, GJ | 1 |
| Mougenot, N | 1 |
| Médiani, O | 1 |
| Wang, B | 1 |
| Song, WH | 1 |
| Liu, GZ | 1 |
| Sein Anand, J | 1 |
| Chodorowski, Z | 1 |
| Hajduk, A | 1 |
| Mychka, VB | 1 |
| Chazova, IE | 1 |
| Gornostaev, VV | 1 |
| Sergienko, VB | 1 |
| Ilgenli, TF | 1 |
| Kilicaslan, F | 1 |
| Kirilmaz, A | 1 |
| Uzun, M | 1 |
| Jiang, H | 1 |
| Ke, YN | 1 |
| Paavonen, KJ | 2 |
| Miettinen, HE | 2 |
| Strandberg, T | 2 |
| Tikkanen, I | 2 |
| Tilvis, R | 2 |
| Pentikäinen, PJ | 2 |
| Wernet, A | 1 |
| Sibert, A | 1 |
| Paugam-Burtz, C | 1 |
| Geffroy, A | 1 |
| Pease, S | 1 |
| Belghiti, J | 1 |
| Vilgrain, V | 1 |
| Mantz, J | 1 |
| Gumbatov, NB | 1 |
| Nishio, M | 1 |
| Sakata, Y | 1 |
| Mano, T | 1 |
| Ohtani, T | 1 |
| Takeda, Y | 1 |
| Miwa, T | 1 |
| Hori, M | 1 |
| Masuyama, T | 1 |
| Kondo, T | 1 |
| Yamamoto, K | 1 |
| Bukhonkina, IuM | 1 |
| Pavlova, LN | 1 |
| Donner, K | 1 |
| Leeman, M | 1 |
| van de Borne, P | 1 |
| Collart, F | 1 |
| Vandenhoven, G | 1 |
| Peeters, L | 1 |
| Mélot, C | 1 |
| Degaute, JP | 1 |
| Uehara, Y | 1 |
| Takada, S | 1 |
| Hirawa, N | 1 |
| Kawabata, Y | 1 |
| Ohshima, N | 1 |
| Numabe, A | 1 |
| Ishimitsu, T | 1 |
| Goto, A | 1 |
| Omata, M | 1 |
| Prisant, LM | 5 |
| Weir, MR | 5 |
| Papademetriou, V | 5 |
| Weber, MA | 3 |
| Adegbile, IA | 1 |
| Alemayehu, D | 4 |
| Lefkowitz, MP | 3 |
| Carr, AA | 2 |
| Johns, TE | 1 |
| Lopez, LM | 1 |
| Wheeldon, NM | 1 |
| Prasad, N | 1 |
| Maclean, D | 2 |
| Peebles, L | 1 |
| McDevitt, DG | 2 |
| Abellán, J | 1 |
| García-Sánchez, FA | 1 |
| Martínez-Selva, JM | 1 |
| Menárguez, FH | 1 |
| Navarro, N | 1 |
| Saavedra, T | 1 |
| de Teresa, E | 1 |
| González, M | 1 |
| Camacho-Vázquez, C | 1 |
| Tabuenca, MJ | 1 |
| Frishman, WH | 2 |
| Burris, JF | 1 |
| Mroczek, WJ | 2 |
| Simon, JS | 2 |
| Chen, SY | 1 |
| Bryzinski, BS | 3 |
| Kuriyama, S | 1 |
| Van de Ven, LL | 4 |
| Van Leeuwen, JT | 1 |
| Smit, AJ | 1 |
| Surman, AJ | 1 |
| Fenichel, RR | 1 |
| Lipicky, RJ | 1 |
| Benetos, A | 3 |
| Poitevin, P | 1 |
| Prost, PL | 2 |
| Safar, ME | 4 |
| Levy, BI | 1 |
| Davidov, ME | 1 |
| Singh, SP | 1 |
| Vlachakis, ND | 2 |
| Blumenthal, JB | 1 |
| Koury, KJ | 1 |
| Fagan, TC | 2 |
| Coulson, LR | 1 |
| DeQuattro, VL | 1 |
| Dukart, G | 1 |
| Goldberg, JD | 1 |
| Koury, K | 1 |
| Soucek, M | 1 |
| Prásek, J | 1 |
| Spinarová, L | 1 |
| Spinar, J | 1 |
| Zicha, J | 1 |
| Vítovec, J | 1 |
| Lewin, AJ | 1 |
| Lueg, MC | 1 |
| Targum, S | 1 |
| Cardenas, P | 1 |
| Haustein, KO | 2 |
| Díez, J | 1 |
| Laviades, C | 1 |
| Mayor, G | 1 |
| Neutel, JM | 5 |
| Smith, DH | 2 |
| Ram, CV | 2 |
| Kaplan, NM | 1 |
| Kazempour, MK | 2 |
| Lithell, H | 3 |
| Weiner, L | 7 |
| Vessby, B | 2 |
| Nordström, ML | 1 |
| Motz, W | 1 |
| Vogt, M | 1 |
| Scheler, S | 1 |
| Schwartzkopff, B | 2 |
| Strauer, BE | 2 |
| Pizarro, E | 1 |
| Giménez, G | 1 |
| Lucas, A | 1 |
| Gressin, V | 2 |
| Humbert, R | 1 |
| Carré, A | 1 |
| Saunders, E | 1 |
| Neutel, J | 1 |
| Tanaka, M | 1 |
| Ishizaka, Y | 1 |
| Ishiyama, Y | 1 |
| Kato, J | 2 |
| Kida, O | 1 |
| Kitamura, K | 1 |
| Kangawa, K | 1 |
| Eto, T | 1 |
| Kulbertus, H | 1 |
| Vaïsse, B | 1 |
| Herpin, D | 1 |
| Asmar, R | 2 |
| Battistella, P | 1 |
| Zannad, F | 1 |
| Boutelant, S | 1 |
| Lyon, A | 1 |
| Conte, D | 1 |
| Denis, J | 1 |
| Honore, P | 2 |
| Contard, S | 1 |
| Mallion, JM | 1 |
| Poggi, L | 1 |
| de Hoon, JN | 2 |
| Vanmolkot, FH | 2 |
| Van Bortel, LM | 3 |
| Dominguez, LJ | 1 |
| Barbagallo, M | 1 |
| Jacober, SJ | 1 |
| Jacobs, DB | 1 |
| Sowers, JR | 1 |
| Albrecht, M | 1 |
| Haneda, T | 1 |
| Ido, A | 1 |
| Fujikane, T | 1 |
| Tanaka, H | 1 |
| Tanazawa, S | 1 |
| Morimoto, H | 1 |
| Kanaya, K | 1 |
| Honda, H | 1 |
| Sakai, H | 1 |
| Akita, N | 1 |
| Hirayama, T | 1 |
| Onodera, S | 1 |
| Kikuchi, K | 1 |
| Holmer, SR | 1 |
| Hense, HW | 1 |
| Danser, AH | 1 |
| Mayer, B | 1 |
| Riegger, GA | 1 |
| Broncel, M | 1 |
| Chojnowska-Jezierska, J | 1 |
| Adamska-Dyniewska, H | 1 |
| Ferdinand, K | 1 |
| DeQuattro, V | 2 |
| Hall, WD | 2 |
| Durand, JM | 1 |
| Gauthier, C | 1 |
| Salas, S | 1 |
| Fogari, R | 2 |
| Zoppi, A | 1 |
| Corradi, L | 1 |
| Preti, P | 1 |
| Mugellini, A | 1 |
| Lusardi, P | 1 |
| Luna, RL | 1 |
| Oigman, W | 1 |
| Ramirez, JA | 1 |
| Mion, D | 1 |
| Batlouni, M | 1 |
| da Rocha, JC | 1 |
| Feitosa, GS | 1 |
| Castro, I | 1 |
| Chaves Júnior, Hde C | 1 |
| God, EM | 1 |
| Maia, LN | 1 |
| Ortega, KC | 1 |
| Raineri, AM | 1 |
| Iranzo, A | 1 |
| Santamaria, J | 1 |
| Brion, R | 1 |
| Carré, F | 1 |
| Verdier, JC | 1 |
| Douard, H | 1 |
| Page, E | 1 |
| Amoretti, R | 1 |
| Gauthier, J | 1 |
| Ducardonnet, A | 1 |
| Dubanchet, A | 2 |
| Kanegae, K | 1 |
| Hiroshige, K | 1 |
| Suda, T | 1 |
| Iwamoto, M | 1 |
| Ohta, T | 1 |
| Nakashima, Y | 1 |
| Ohtani, A | 1 |
| Bulpitt, CJ | 1 |
| Connor, M | 1 |
| Schulte, M | 1 |
| Fletcher, AE | 1 |
| Badilini, F | 1 |
| Maison-Blanche, P | 1 |
| Champomier, P | 1 |
| Provost, JC | 1 |
| Coumel, P | 1 |
| Milon, H | 1 |
| Consoli, S | 2 |
| Safavian, A | 1 |
| Safar, M | 2 |
| Hong, T | 1 |
| Zhang, R | 1 |
| Yang, X | 1 |
| Owada, A | 1 |
| Suda, S | 1 |
| Hata, T | 1 |
| Miyake, S | 1 |
| Wallukat, G | 1 |
| Nissen, E | 1 |
| Gosse, P | 1 |
| Roudaut, R | 1 |
| Herrero, G | 2 |
| Dallocchio, M | 1 |
| Giesecke, HG | 1 |
| Buchner-Möll, D | 1 |
| Bouvier, JM | 1 |
| Rabot, D | 1 |
| Höffler, D | 1 |
| Morgenstern, HO | 1 |
| Bueno, J | 1 |
| Amiguet, JA | 1 |
| Carasusan, J | 1 |
| Cebollada, J | 1 |
| Carretero, J | 2 |
| Fauvel, JP | 2 |
| Hadj-Aissa, A | 2 |
| Laville, M | 2 |
| Pozet, N | 2 |
| Bernard, N | 1 |
| Sassard, J | 1 |
| Zech, P | 2 |
| Laurent, SA | 1 |
| London, GM | 1 |
| Lohmann, FW | 1 |
| Loesment, WA | 1 |
| Kaehler, H | 1 |
| Prichard, BN | 1 |
| Saul, PA | 1 |
| Oliván Martinez, J | 1 |
| Garcia, MJ | 1 |
| Rodriguez Botaro, A | 1 |
| Pizarro, JL | 1 |
| Garrido, M | 1 |
| Salvador, M | 2 |
| Chamontin, B | 2 |
| Begasse, F | 2 |
| Amar, J | 1 |
| Ito, A | 1 |
| Egashira, K | 1 |
| Narishige, T | 1 |
| Muramatsu, K | 1 |
| Takeshita, A | 1 |
| Girerd, X | 1 |
| Redon, J | 1 |
| Rovira, E | 1 |
| Miralles, A | 1 |
| Julve, R | 1 |
| Pascual, JM | 1 |
| Deary, AJ | 1 |
| Schumann, AL | 1 |
| Murfet, H | 1 |
| Haydock, SF | 1 |
| Foo, RS | 1 |
| Onodera, T | 1 |
| Okazaki, F | 1 |
| Miyazaki, H | 1 |
| Minami, S | 1 |
| Ito, T | 1 |
| Seki, S | 1 |
| Taniguchi, M | 1 |
| Taniguchi, I | 1 |
| Mochizuki, S | 1 |
| Adamopoulos, C | 1 |
| Argyriadis, P | 1 |
| Bean, K | 1 |
| Sorof, JM | 1 |
| Cargo, P | 1 |
| Graepel, J | 1 |
| Humphrey, D | 1 |
| King, E | 1 |
| Rolf, C | 1 |
| Cunningham, RJ | 1 |
| Breed, JG | 1 |
| Ciampricotti, R | 1 |
| Tromp, GP | 1 |
| Valster, FA | 1 |
| Lageweg, E | 1 |
| Broekman, CP | 1 |
| Haensel, SM | 1 |
| Slob, AK | 1 |
| Mengden, T | 3 |
| Binswanger, B | 1 |
| Weisser, B | 2 |
| Vetter, W | 3 |
| Bättig, B | 1 |
| Schubert, M | 2 |
| Jeck, T | 2 |
| Buddeberg, C | 1 |
| Aranda, P | 1 |
| Lopez, S | 1 |
| Fernandez, JA | 1 |
| Lopez de Novales, E | 1 |
| Oral, I | 2 |
| Vareka, I | 2 |
| Marek, D | 2 |
| Vulpis, V | 1 |
| Antonacci, A | 1 |
| Prandi, P | 1 |
| Bokor, D | 1 |
| Pirrelli, A | 1 |
| Asmar, RG | 1 |
| Kerihuel, JC | 1 |
| Girerd, XJ | 1 |
| Doche, C | 1 |
| Dixon, MS | 1 |
| Thomas, P | 2 |
| Sheridan, DJ | 1 |
| Graffius, D | 1 |
| Edmonds, D | 1 |
| Guittard, J | 1 |
| Desnoyers, M | 1 |
| Westcott, RJ | 1 |
| Zinny, MA | 1 |
| O'Donnell, DM | 1 |
| Bryzinski, B | 1 |
| McKee, B | 1 |
| Nelson, BR | 1 |
| Bracchetti, D | 1 |
| Gradnik, R | 1 |
| Alberti, A | 1 |
| Brunelli, A | 1 |
| Orselli, L | 1 |
| Leonardi, G | 1 |
| Pavesi, PC | 1 |
| Cantelli, I | 1 |
| Frithz, G | 5 |
| Kirsten, R | 1 |
| Neff, J | 1 |
| Heintz, B | 1 |
| Nemeth, N | 1 |
| Rahlfs, VW | 1 |
| Nelson, K | 1 |
| Bühler, FR | 1 |
| Berglund, G | 1 |
| Anderson, OK | 1 |
| Brunner, HR | 1 |
| Scherrer, U | 1 |
| van Brummelen, P | 1 |
| Distler, A | 1 |
| Philipp, T | 1 |
| Mimran, A | 1 |
| Selinus, I | 2 |
| Ikeda, M | 1 |
| Inagaki, Y | 1 |
| Iimura, O | 1 |
| Kuramoto, K | 1 |
| Takeda, T | 1 |
| Haeusler, G | 1 |
| Schliep, HJ | 1 |
| Schelling, P | 1 |
| Becker, KH | 1 |
| Klockow, M | 1 |
| Minck, KO | 1 |
| Enenkel, HJ | 1 |
| Schulze, E | 1 |
| Bergmann, R | 1 |
| Schmitges, CJ | 1 |
| Chatterjee, SS | 1 |
| Esper, RJ | 1 |
| Esper, RC | 1 |
| Burrieza, OH | 1 |
| Menna, J | 1 |
| Janka, HU | 1 |
| Ziegler, AG | 1 |
| Disselhoff, G | 2 |
| Mehnert, H | 1 |
| Bethge, H | 2 |
| Litterer, G | 1 |
| Wagner, G | 1 |
| Prager, G | 1 |
| Grevel, J | 1 |
| Whiting, B | 1 |
| Burkart, F | 1 |
| Stamm, G | 1 |
| Witassek, F | 1 |
| Cardona, R | 1 |
| Lizarraga, P | 1 |
| Orozco, M | 1 |
| Perez-Acuna, F | 1 |
| Monsalve, P | 1 |
| Vera, O | 1 |
| Lopez, B | 1 |
| Schmidt-Dommerque, F | 1 |
| Tremarias, A | 1 |
| Hugues, C | 1 |
| Pannier, B | 1 |
| Daou, J | 1 |
| Lancaster, SG | 1 |
| Sorkin, EM | 1 |
| Lewis, R | 1 |
| Ioannides, C | 1 |
| Johnston, A | 1 |
| Haasis, R | 1 |
| Hosie, J | 1 |
| Amabile, G | 1 |
| Serradimigni, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis.[NCT04085562] | Phase 4 | 46 participants (Actual) | Interventional | 2019-09-01 | Completed | ||
| Multicenter Observational Open Program. Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril in Patients With Arterial Hypertension and Stable CAD in Daily Clinical Practice (STYLE)[NCT03730116] | 1,909 participants (Actual) | Observational | 2018-11-14 | Completed | |||
| Resistant Hypertension On Treatment - Sequential Nephron Blockade Compared to Dual Blockade of the Renin-angiotensin-aldosterone System Plus Bisoprolol in the Treatment of Resistant Arterial Hypertension: A Randomized Trial (ResHypOT)[NCT02832973] | Phase 4 | 72 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Optimum Treatment for Drug-Resistant Hypertension[NCT02369081] | Phase 4 | 348 participants (Actual) | Interventional | 2009-05-31 | Active, not recruiting | ||
| Newer vs Older Antihypertensive Agents in African Hypertensive Patients Trial[NCT01030458] | Phase 4 | 183 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| A Randomized Controlled Study: Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension[NCT01762436] | Phase 4 | 109 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension[NCT03276598] | Phase 4 | 233 participants (Actual) | Interventional | 1999-11-25 | Completed | ||
| Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia：A Multicenter Randomized Controlled Study[NCT05688579] | Phase 4 | 8,000 participants (Anticipated) | Interventional | 2023-04-16 | Enrolling by invitation | ||
| HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial[NCT03476616] | Phase 4 | 330 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension[NCT05275907] | Phase 4 | 0 participants (Actual) | Interventional | 2022-07-12 | Withdrawn (stopped due to Screened participants did not meet inclusion criteria prior to study completion date) | ||
| An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE)[NCT02398929] | Phase 4 | 100 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| A Prospective, Multicentre, Open-label, Single-arm Interventional Study of Bisoprolol (Nerkardou) (Between Low Dose and High Dose) 5 and 10 mg ODF Treatment In Egyptian Patients With Essential Hypertension[NCT05880056] | Phase 4 | 827 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
| The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease[NCT03775096] | Phase 2 | 15 participants (Anticipated) | Interventional | 2019-04-04 | Recruiting | ||
| Comparison of Single and Combination Diuretics in Low-Renin Hypertension[NCT02351973] | Phase 4 | 423 participants (Actual) | Interventional | 2009-11-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Changes in the mean office diastolic BP levels (in mm Hg) in the sitting position among the patints with HT and CAD recieving bis/perindopril FDC (NCT03730116)
Timeframe: 3 months
| Intervention | mm Hg (Mean) |
|---|---|
| Mean Office DBP Changes Between v3 vs Baseline | 15.9 |
The percentage of the patients achieved the target levels of clinical BP among included patients ( SBP < 140 mm Hg and DBP < 90 mm Hg) with HT and stable CAD recieving Bisoprolol/Perindopril FDC (NCT03730116)
Timeframe: 3 month
| Intervention | Participants (Count of Participants) |
|---|---|
| the Patients With HT and Concomitant Stable CAD | 1640 |
Average decrease of the number of angina attacks in patients with HT and stable CAD who recieved the bisoprolol/perindopril FDC (NCT03730116)
Timeframe: 3 month
| Intervention | number of angina attacks per week (Mean) |
|---|---|
| the Patients With HT and Concomitant Stable CAD | -3.2 |
"Percentage of the patients with definite answer on question from questionnaire regarding adherence; (Compliance evaluation test - 6 questions tes; Answer No to all questions: good compliance; Answer Yes to 1-2 questions: minor compliance; Answer Yes to 3 or more questions: noncompliance)" (NCT03730116)
Timeframe: 3 month
| Intervention | Participants (Count of Participants) |
|---|---|
| the Patients With HT and Concomitant Stable CAD | 1827 |
Changes of the score in the visual analog scale (VAS) to assess the wellbeing; (minimum score 0 mm and maximum score 100 mm) among patients with HT and CAD recieving biso/perindopril FDC (NCT03730116)
Timeframe: 3 month
| Intervention | units on a scale - mm (Mean) |
|---|---|
| the Patients With HT and Concomitant Stable CAD | 35.1 |
Changes in the mean office systolic BP levels (in mm Hg) in the sitting position (NCT03730116)
Timeframe: 3 months
| Intervention | mm Hg (Mean) |
|---|---|
| Mean of SBP Changes | 31.5 |
This variable gives the proportion of patients reaching blood pressure control over time (< 140 mmHg systolic and < 90 mmHg diastolic) (NCT01030458)
Timeframe: 6 months follow-up after randomization
| Intervention | participants (Number) |
|---|---|
| Amlodipine Plus Valsartan | 58 |
| Hydrochlorothiazide Plus Bisoprolol | 40 |
(NCT01030458)
Timeframe: 6 months follow-up after randomization
| Intervention | participants (Number) |
|---|---|
| Amlodipine Plus Valsartan | 1 |
| Hydrochlorothiazide Plus Bisoprolol | 1 |
Blood pressure is measured by means of validated oscillometric OMRON 705IT recorders (OMRON Healthcare Europe BV, Nieuwegein, Netherlands), after the patient has been seated for 5 minutes in a quiet room, according to the ESC/ESH guidelines. Three consecutive blood pressure readings are obtained and the average of these 3 measurements is used as the primary outcome. (NCT01030458)
Timeframe: 6 months follow-up after randomization
| Intervention | mmHg (Mean) |
|---|---|
| Amlodipine Plus Valsartan | 127.2 |
| Hydrochlorothiazide Plus Bisoprolol | 134.1 |
The time (in weeks) after randomisation that will be required to reach and maintain the target, defined as a blood pressure below 140 mmHg systolic and 90 mmHg diastolic. (NCT01030458)
Timeframe: 6 months follow-up after randomization
| Intervention | weeks (Median) |
|---|---|
| Amlodipine Plus Valsartan | 12 |
| Hydrochlorothiazide Plus Bisoprolol | 18 |
17 reviews available for bisoprolol and Blood Pressure, High
| Article | Year |
|---|---|
A growing evidence base for the fixed-dose combination of bisoprolol and amlodipine to manage hypertension.
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Drug Combinations; Humans; Hyperten | 2022 |
Genome-Wide Meta-Analysis of Blood Pressure Response to β
Topics: ADP-ribosyl Cyclase; Adrenergic beta-1 Receptor Antagonists; Antigens, CD; Atenolol; Bisoprolol; Bla | 2019 |
Recent advances in understanding and managing resistant/refractory hypertension.
Topics: Antihypertensive Agents; Bisoprolol; Catheters; Clinical Trials as Topic; Clonidine; Denervation; Do | 2020 |
Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk.
Topics: Bisoprolol; Humans; Hypertension; Hypertrophy, Left Ventricular | 2021 |
Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.
Topics: Adrenergic beta-Antagonists; Benzopyrans; Bisoprolol; Cardiovascular Diseases; Ethanolamines; Heart | 2022 |
Three drugs and still hypertensive: what's left?
Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; Doxazosin; Drug Therapy, Combination; Humans; H | 2016 |
Carvedilol and bisoprolol as initial therapy for adult hypertension without compelling indications.
Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; Carvedilol; Humans; Hypertension; Treatment Out | 2019 |
[The benefits of carvedilol therapy in the treatment of patients with high cardiovascular risk].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Bisoprolol; Carbazoles; Cardi | 2016 |
[Beta-adrenoblockers in arterial hypertension: focus on bisoprolol].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Blood Pressure; Humans; Hypertension; Treatment Outcome | 2010 |
[Bisoprolol: opportunities in the treatment of hypertension].
Topics: Adrenergic beta-1 Receptor Antagonists; Biological Availability; Bisoprolol; Comorbidity; Coronary D | 2012 |
Beta-blockers and diabetes: the bad guys come good.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Bisoprolol; Coronary Disease; Diabet | 2002 |
Bisoprolol: is this just another beta-blocker for hypertension or angina?
Topics: Angina Pectoris; Bisoprolol; Clinical Trials as Topic; Drug Interactions; Electrophysiology; Hemodyn | 1995 |
Beta-blockade and brachial artery hemodynamics in hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Bisoprolol; Brachial Artery; Forearm; Humans; Hypert | 1990 |
Beta-receptor blockade, physical activity, and metabolism.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Blood Pressure; Glucose; Heart Rate; Humans; Hypertension; | 1990 |
Comparison of beta-blockade and ACE inhibitors in the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bisoprolol; Blood Pr | 1990 |
Clinical results with bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg combination in systolic hypertension in the elderly.
Topics: Aged; Antihypertensive Agents; Bisoprolol; Dose-Response Relationship, Drug; Double-Blind Method; Dr | 2002 |
Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Bisoprolol; Humans; Hypertension; Propanolami | 1988 |
115 trials available for bisoprolol and Blood Pressure, High
| Article | Year |
|---|---|
Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.
Topics: Amlodipine; Antihypertensive Agents; Australia; Bisoprolol; Blood Pressure; Double-Blind Method; Dru | 2021 |
Influence of Moxonidine and Bisoprolol on Morphofunctional Condition of Arterial Wall and Telomerase Activity in Postmenopausal Women with Arterial Hypertension and Osteopenia. The Results from a Moscow Randomized Study.
Topics: Antihypertensive Agents; Bisoprolol; Bone Diseases, Metabolic; Carotid Intima-Media Thickness; Femal | 2022 |
Effect of amlodipine versus bisoprolol in hypertensive patients on maintenance hemodialysis: A randomized controlled trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Female; Humans; Hypert | 2021 |
An anchored simulated treatment comparison of uptitration of amlodipine compared with a low-dose combination treatment with amlodipine 5 mg/bisoprolol 5 mg for patients with hypertension suboptimally controlled by amlodipine 5 mg monotherapy.
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Drug Combinations; Humans; Hyperten | 2022 |
Effect of Sequential Nephron Blockade versus Dual Renin-Angiotensin System Blockade Plus Bisoprolol in the Treatment of Resistant Hypertension, a Randomized Controlled Trial (Resistant Hypertension on Treatment - ResHypOT).
Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Humans; | 2022 |
Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Bisoprolol; Calcium Channel Blocke | 2021 |
Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease.
Topics: Antihypertensive Agents; Bisoprolol; Clinical Studies as Topic; Humans; Hypertension; Japan; Pulmona | 2017 |
Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized control
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; A | 2018 |
[Analysis of variability of cardiac rhythm and sexual function in men with arterial hypertension during therapy with biosporolol and nebivolol].
Topics: Adult; Antihypertensive Agents; Benzopyrans; Bisoprolol; Blood Pressure; Circadian Rhythm; Dose-Resp | 2012 |
[Effect of monotherapy with nebivolol, bisoprolol, carvedilol on the state of vegetative nervous system and sexual function in men with arterial hypertension].
Topics: Adult; Antihypertensive Agents; Benzopyrans; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Dru | 2013 |
Bisoprolol improved endothelial function and myocardium survival of hypertension with stable angina: a randomized double-blinded trial.
Topics: Angina, Stable; Bisoprolol; Double-Blind Method; Endothelium, Vascular; Female; Heart; Humans; Hyper | 2013 |
Efficacy of newer versus older antihypertensive drugs in black patients living in sub-Saharan Africa.
Topics: Adult; Africa South of the Sahara; Amlodipine; Antihypertensive Agents; Bisoprolol; Black People; Dr | 2013 |
A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension.
Topics: Adult; Antihypertensive Agents; Arterial Pressure; Atenolol; Baroreflex; Bisoprolol; Essential Hyper | 2013 |
Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyp | 2013 |
Comparison of efficacy and safety between bisoprolol transdermal patch (TY-0201) and bisoprolol fumarate oral formulation in Japanese patients with grade I or II essential hypertension: randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Asian People; Bisoprolol; Blood Pressure; Dose | 2013 |
[Efficacy and safety of bisoprololal in hypertensive patients with cardiovascular disease and chronic obstructive pulmonary disease].
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Cardiovascular Di | 2014 |
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.
Topics: Adolescent; Adult; Aged; Aldosterone; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers | 2014 |
Effects of Celiprolol and Bisoprolol on Blood Pressure, Vascular Stiffness, and Baroreflex Sensitivity.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Ankle Brachial Index; Antihypertensive Agents; | 2015 |
Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
Topics: Adult; Aldehyde Oxidoreductases; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compo | 2015 |
[Amlodipine and bisoprolol application in patients with arterial hypertension].
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Pressure Monitoring, Ambulato | 2014 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2015 |
[Pharmacoeconomic Efficacy of a Fixed Combination of Bisoprolol and Amlodipine].
Topics: Aged; Amlodipine; Antihypertensive Agents; Aorta; Bisoprolol; Blood Pressure; Costs and Cost Analysi | 2015 |
Population Pharmacokinetics of Bisoprolol in Hemodialysis Patients with Hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bis | 2016 |
[PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension].
Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; Diuretics; Doxazosin; Drug Therapy, Combination | 2015 |
PURLs: Resistant hypertension? Time to consider this fourth-line drug.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bi | 2016 |
Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study.
Topics: Adult; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; D | 2017 |
Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men.
Topics: Action Potentials; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Cross-Over Studi | 2009 |
Effects of AT1 receptor and beta1 receptor blocking on blood pressure, peripheral hemodynamic and lipid profile in statin-treated hypertensive hypercholesterolemic patients.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Bloc | 2009 |
One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study.
Topics: Adult; Antihypertensive Agents; Bisoprolol; Double-Blind Method; Female; Heart; Heart Function Tests | 2009 |
Changes in platelet size and spleen volume in response to selective and non-selective beta-adrenoceptor blockade in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Bisoprolol; Blood Platelets; Carbazoles | 2009 |
The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines.
Topics: Adult; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2009 |
Effects of bisoprolol and cilazapril on the central retinal artery blood flow in patients with essential hypertension--preliminary results.
Topics: Adult; Antihypertensive Agents; Bisoprolol; Blood Flow Velocity; Blood Pressure; Cilazapril; Humans; | 2010 |
Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial.
Topics: Adult; Africa South of the Sahara; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Black Peop | 2011 |
Plasma fibrin clot properties in arterial hypertension and their modification by antihypertensive medication.
Topics: Adult; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Coagulation; Female; Fibrin; Humans; H | 2012 |
Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients.
Topics: Administration, Oral; Adult; Africa South of the Sahara; Aged; Amlodipine; Amlodipine, Valsartan Dru | 2012 |
Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study.
Topics: Adolescent; Adult; Aged; Amiloride; Angiotensin-Converting Enzyme Inhibitors; Biological Transport; | 2012 |
Efficacy of domestic bisoprolol,enalapril and nifedipine retard in mild to moderate hypertension: a randomized double-blind multicenter clinical trial in China.
Topics: Bisoprolol; Blood Pressure; China; Double-Blind Method; Enalapril; Humans; Hypertension; Nifedipine | 2002 |
Relationships between the antihypertensive effects of bisoprolol and levels of plasma atrial natriuretic peptide in hypertensive patients.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atrial Natriuretic Factor; Bisoprolol; Blood Press | 2002 |
[Efficacy and safety of different beta-blockers in patients with isolated systolic hypertension associated with diabetes mellitus and obstructive pulmonary diseases].
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Blood Pressure; Blood Pressure Monitoring, Ambula | 2003 |
Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Benzopyrans; Bisoprolol; Blood Pressure; Ethanolamines; Fe | 2003 |
Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation.
Topics: Adult; Aged; Aldosterone; Amlodipine; Antihypertensive Agents; Bisoprolol; Cross-Over Studies; Femal | 2004 |
[The effect long-term administration of a selective beta1 blocker bisoprolol on glucose metabolism in patients with essential hypertensive and type 2 diabetes mellitus].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Bisoprolol; Blood Glu | 2005 |
[The clinical efficiency and safety of bisoprolol hydrochlorothiazide in patients with mild to moderate essential hypertension].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bisoprolol; Drug Combinations; Humans; Hydrochloro | 2006 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Calcium; Cross-Over Studies; | 2008 |
Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure.
Topics: Adult; Atenolol; Bisoprolol; Blood Pressure; Cardiac Output; Double-Blind Method; Female; Glomerular | 1993 |
Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Bisoprolol; Blood Pressure; Double-Blind Method; Drug | 1995 |
A double-blind comparison of bisoprolol and atenolol in patients with essential hypertension.
Topics: Atenolol; Bisoprolol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; H | 1995 |
Effects of bisoprolol on left ventricular hypertrophy in essential hypertension.
Topics: Adult; Aged; Bisoprolol; Echocardiography, Doppler; Exercise Test; Female; Gated Blood-Pool Imaging; | 1994 |
First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension.
Topics: Aged; Bisoprolol; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hy | 1995 |
The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial.
Topics: Adult; Aged; Bisoprolol; Cross-Over Studies; Female; Humans; Hypertension; Intermittent Claudication | 1994 |
Bisoprolol, a once-a-day beta-blocking agent for patients with mild to moderate hypertension.
Topics: Adult; Bisoprolol; Blood Glucose; Blood Pressure; Cholesterol; Dose-Response Relationship, Drug; Dou | 1994 |
A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide.
Topics: Bisoprolol; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochl | 1994 |
[Atenolol and bisoprolol in the treatment of mild and moderately severe hypertension].
Topics: Adult; Atenolol; Bisoprolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Male | 1993 |
A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension.
Topics: Bisoprolol; Blood Pressure Monitors; Drug Combinations; Female; Hemodynamics; Humans; Hydrochlorothi | 1993 |
[The blood pressure lowering effect of bisoprolol, a beta 1-selective receptor blocker--a multicenter study in general practice conditions].
Topics: Bisoprolol; Blood Pressure; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Hypertensi | 1993 |
Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents.
Topics: Adult; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Blood Pressure; Blood Pressure Determination; | 1993 |
Effects of small doses of bisoprolol on blood pressure and lipoprotein concentrations in hypertensive patients.
Topics: Adult; Aged; Bisoprolol; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relations | 1993 |
Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group.
Topics: Adult; Age Factors; Aged; Ambulatory Care; Atenolol; Bisoprolol; Black People; Blood Pressure; Doubl | 1993 |
[Effects of bisoprolol and ramipril on short-term variability of systolic blood pressure during mental stress test: spectrum analysis].
Topics: Adult; Antihypertensive Agents; Bisoprolol; Blood Pressure; Double-Blind Method; Female; Heart Rate; | 1995 |
Chronic effect of beta-adrenoceptor blockade on plasma levels of brain natriuretic peptide during exercise in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atrial Natriuretic Factor; Bisoprolol; | 1996 |
Assessment of antihypertensive effect by blood pressure monitoring: applications to bisoprolol and lisinopril in a double-blind study.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biso | 1997 |
Quality of life comparison between bisoprolol and nifedipine retard in hypertension.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bisoprolol; Blood Pre | 1997 |
Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Captopril; | 1997 |
[Effect of bisoprolol, a beta 1-selective beta-blocker, on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Female; Glucose; Humans; Hyp | 1998 |
Efficacy of low-dose combination of bisoprolol/hydrochlorothiazide compared with amlodipine and enalapril in men and women with essential hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Dose-Response Relation | 1998 |
Bisoprolol in the treatment of hypertension in the elderly.
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Bisoprolol; Blood Pressure Determination; Female; | 1998 |
Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks.
Topics: Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Bisoprolol; Black People; Chi-Squar | 1999 |
Low-dose combination treatment for hypertension versus single-drug treatment-bisoprolol/hydrochlorothiazide versus amlodipine, enalapril, and placebo: combined analysis of comparative studies.
Topics: Amlodipine; Bisoprolol; Double-Blind Method; Drug Therapy, Combination; Enalapril; Humans; Hydrochlo | 1998 |
Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Analysis of Variance; Atenolol; Bisopr | 1999 |
[Efficacy and tolerance of the bisoprolol/hydrochlorothiazide combination in arterial hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Bisoprolol; Drug Combinations; Female; Follow-Up Studies; Huma | 1998 |
Impact of antihypertensive treatment on quality of life: comparison between bisoprolol and bendrofluazide.
Topics: Adult; Aged; Antihypertensive Agents; Bendroflumethiazide; Bisoprolol; Blood Pressure; Cross-Over St | 1999 |
Comparative effects of bisoprolol and nitrendipine on exercise capacity in hypertensive patients with regular physical activity.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bisoprolol; Blood Pressure; Double-Blind Method; E | 2000 |
Bisoprolol and nifedipine retard in elderly hypertensive patients: effect on quality of life.
Topics: Adrenergic beta-Agonists; Affect; Aged; Aging; Antihypertensive Agents; Bisoprolol; Calcium Channel | 2000 |
Frequency-domain heart rate variability in 24-hour Holter recordings: role of spectral method to assess circadian patterns and pharmacological autonomic modulation.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Circadian Rhythm; Electrocardiogra | 2000 |
Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Bisoprolol; Blood Pressure; Blood Pressure Monitoring | 2000 |
The effects of verapamil SR and bisoprolol on reducing the sympathetic nervous system's activity.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Bisoprolol; Blood Pressure; Calcium Channel Blockers; Endo | 2000 |
The effects of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Blood Glucose; Blood Pressure; Female; Glucose; Glucose Tol | 2001 |
Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibi | 1990 |
Effect of bisoprolol and acebutolol on resting blood pressure and on exercise blood pressure profile in hypertensive patients: a comparative, single-blind study.
Topics: Acebutolol; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Pressure; Chi-Sq | 1990 |
Bisoprolol vs. chlorthalidone: a randomized, double-blind, comparative study in arterial hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Bisoprolol; Blood Pressure; Chi-Square | 1990 |
Bisoprolol and nifedipine SR in the treatment of hypertension in the elderly.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Blood Pressure; Calcium Channel Bl | 1990 |
Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihyper | 2002 |
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting | 2002 |
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting | 2002 |
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting | 2002 |
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting | 2002 |
Clinical results with bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg combination in systolic hypertension in the elderly.
Topics: Aged; Antihypertensive Agents; Bisoprolol; Dose-Response Relationship, Drug; Double-Blind Method; Dr | 2002 |
Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Bisoprolol; Blood Pressure; Child; Diuretics; Dose-Response | 2002 |
Quality of life perception during antihypertensive treatment: a comparative study of bisoprolol and enalapril.
Topics: Adult; Aged; Bisoprolol; Blood Pressure; Double-Blind Method; Enalapril; Female; Heart Rate; Humans; | 1992 |
Bisoprolol and hypertension: effects on sexual functioning in men.
Topics: Adult; Bisoprolol; Double-Blind Method; Humans; Hypertension; Male; Middle Aged; Penile Erection; Pr | 1992 |
An evaluation of self-measured blood pressure in a study with a calcium-channel antagonist versus a beta-blocker.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Pressure; Blood Pressure Det | 1992 |
Comparison of casual, ambulatory and self-measured blood pressure in a study of nitrendipine vs bisoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Pressure Determination; Double-Blind Met | 1992 |
Nitrendipine in the therapeutic management of elderly hypertensive patients: results of a multicenter trial. Andalousian Hypertension Group.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Glucose; Blood Pressure; Cholesterol; Female; H | 1992 |
[The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bisoprolol; Blood Glucose; Diabetes Mellitus, Ty | 1991 |
Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Bisoprolol; Blood Pressure; Brachial | 1991 |
A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bisoprolol; Blood Pressure; Double-Blind Method; | 1990 |
[New specialty drugs registered in Austria. Concor].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Austria; Bisoprolol; Clinical Trials as Topic; Coronar | 1990 |
Casual versus ambulatory twenty-four-hour blood pressure measurement in a comparative study with bisoprolol or nitrendipine.
Topics: Adrenergic beta-Antagonists; Adult; Ambulatory Care; Bisoprolol; Blood Pressure; Blood Pressure Moni | 1990 |
Multicenter evaluation of the hemodynamic effects of bisoprolol in patients with mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Pressure; Double-Blind Method; Drug Eval | 1990 |
A double-blind comparison of bisoprolol and captopril for treatment of essential hypertension in the elderly.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Blood Pressure; Captopril; D | 1990 |
Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Pressure; Dose-Response Relationship, Dr | 1986 |
Influence of different bisoprolol doses on hemodynamics, plasma catecholamines, platelet aggregation, and alpha 2- and beta-receptors in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Blood Pressure; Catecholamines; Dose-Response Relationship, | 1986 |
Double-blind comparison of the cardioselective beta-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bisoprolol; Blood Pressure; Clinical Trials as T | 1986 |
A comparison of the effects of bisoprolol and atenolol on lipoprotein concentrations and blood pressure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bisoprolol; Blood Pressure; Female; Humans; Hype | 1986 |
Clinical evaluation of bisoprolol in patients with hypertension: interim report.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Pressure; Clinical Trials as Topic; Hear | 1986 |
The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics.
Topics: Adrenergic beta-Antagonists; Aged; Albuterol; Asthma; Bisoprolol; Blood Pressure; Bronchial Provocat | 1986 |
Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Glucose; Blood Pressure; Body Weight; Carbohydr | 1986 |
[The 24-hour-effect of bisoprolol on blood pressure at rest and during stress].
Topics: Adolescent; Adult; Aged; Bisoprolol; Blood Pressure; Circadian Rhythm; Clinical Trials as Topic; Exe | 1989 |
Population pharmacokinetic analysis of bisoprolol.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Clinical Trials as Topic; Female; Humans; Hypertensio | 1989 |
Antihypertensive effects of bisoprolol during once daily administration in patients with essential hypertension. A dose-ranging study with parallel groups.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Pressure; Clinical Trials as Topic; Doub | 1986 |
[Intraindividual comparison of 2 bisoprolol dosages in patients with essential hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Clinical Trials as Topic; Dose-Response Relationship | 1986 |
Bisoprolol versus hydrochlorothiazide plus amiloride in essential hypertension, a randomized double-blind study.
Topics: Adrenergic beta-Antagonists; Adult; Amiloride; Bisoprolol; Blood Pressure; Double-Blind Method; Drug | 1987 |
A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Bisoprolol; Blood Pressure; Clinical Trials as Topic; | 1988 |
Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET).
Topics: Adolescent; Adult; Aged; Bisoprolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; | 1987 |
Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study.
Topics: Adult; Aged; Atenolol; Bisoprolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Dr | 1987 |
Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind trial.
Topics: Aged; Aging; Bisoprolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Heart Rate; | 1987 |
125 other studies available for bisoprolol and Blood Pressure, High
| Article | Year |
|---|---|
Effect of bisoprolol on central aortic systolic pressure in Chinese hypertensive patients after the initial dose and long-term treatment.
Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; China; Cohort Studies; Humans; Hypertension; Mi | 2022 |
Concomitant Treatment of Hypertensive Patients with Bisoprolol and Perindopril in Routine Clinical Practice: A Post Hoc Analysis of the CONFIDENCE II, PROTECT I, and PROTECT III Observational Studies.
Topics: Aged; Antihypertensive Agents; Bisoprolol; Blood Pressure; Canada; Drug Combinations; Humans; Hypert | 2022 |
The Impact of International Nonproprietary Names Integration on Prescribing Reimbursement Medicines for Arterial Hypertension and Analysis of Medication Errors in Latvia.
Topics: Bisoprolol; Humans; Hypertension; Latvia; Medication Errors; Perindopril; Retrospective Studies | 2022 |
The Effect of Bisoprolol on Premature Ventricular Complex in Vietnamese Patients with Hypertension and Left Ventricular Hypertrophy.
Topics: Bisoprolol; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Quality of Life; Sout | 2023 |
Efficacy of Antihypertensive Drugs of Different Classes After Renal Denervation in Spontaneously Hypertensive Rats.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Bisoprolol; Blood Pressure; Cardiomyopath | 2023 |
Effectiveness and Tolerability of Bisoprolol/Perindopril Single-Pill Combination in Patients with Arterial Hypertension and a History of Myocardial Infarction: The PRIDE Observational Study.
Topics: Aged; Angina Pectoris; Antihypertensive Agents; Bisoprolol; Blood Pressure; Drug Combinations; Femal | 2023 |
Impact of bisoprolol and amlodipine on cardiopulmonary responses and symptoms during exercise in patients with chronic obstructive pulmonary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Bisoprolol; Exercise Test; Humans; Hypertension; Pulmonary | 2023 |
Elevated Blood Pressure Occurs without Endothelial Dysfunction in a Rat Model of Pulmonary Emphysema.
Topics: Animals; Bisoprolol; Blood Pressure; Emphysema; Heart Failure; Hypertension; Male; Pulmonary Disease | 2023 |
Unilateral adrenalectomy for a drug-resistant bilateral primary aldosteronism with heart failure: pathophysiology and surgical indication.
Topics: Adrenal Glands; Adrenalectomy; Aldosterone; Antihypertensive Agents; Bisoprolol; Eplerenone; Heart F | 2023 |
Neonatal effects of intrauterine metoprolol/bisoprolol exposure during the second and third trimester: a cohort study with two comparison groups.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Birth Weight; Bisoprolol; Cohort Studies; Fema | 2020 |
Severe impaired blood pressure control caused by baroreflex failure as a late sequela of neck irradiation.
Topics: Antihypertensive Agents; Baroreflex; Bisoprolol; Blood Pressure; Humans; Hypertension; Hypotension, | 2020 |
[Uncontrolled Arterial Hypertension: Kidney, Neurohormonal Imbalance, and Approaches to Antihypertensive Drug Therapy].
Topics: Antihypertensive Agents; Bisoprolol; Humans; Hypertension; Kidney; Spironolactone | 2019 |
Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Pressure; Female; Heart Failure; Humans; Hypert | 2020 |
Effect of four classes of antihypertensive drugs on cardiac repolarization heterogeneity: A double-blind rotational study.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Bisoprolol; | 2020 |
Resting heart rate control and prognosis in coronary artery disease patients with hypertension previously treated with bisoprolol: a sub-group analysis of the BISO-CAD study.
Topics: Aged; Bisoprolol; China; Coronary Artery Disease; Heart Rate; Humans; Hypertension; Middle Aged; Pro | 2020 |
Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Bisoprolol; Cytochrome P-450 CYP3A; Diabetes Mellitus, Type 2; Femal | 2020 |
INFLUENCE OF COMBINED PHARMACOTHERAPY ON CARDIO-VASCULAR SYSTEM OF ARTERIAL HYPERTENSION (IN EXPERIMENT).
Topics: Animals; Bisoprolol; Endothelial Cells; Heart; Hypertension; Myocardium; Rats | 2020 |
Use of Paediatric Xylometazoline Nasal Drop is not a Child's Play in Hypertensive Patients on Bisoprolol: A Case Report.
Topics: Bisoprolol; Child; Humans; Hypertension; Imidazoles; Male; Middle Aged; Nasal Decongestants | 2021 |
Effectiveness and Tolerability of the Single-Pill Combination of Bisoprolol and Perindopril in Patients with Arterial Hypertension and Stable Coronary Artery Disease in Daily Clinical Practice: The STYLE Study.
Topics: Aged; Antihypertensive Agents; Bisoprolol; Blood Pressure; Coronary Artery Disease; Drug Combination | 2021 |
Head-to-head comparison of the heart rate variability between the bisoprolol transdermal patch and bisoprolol fumarate tablet.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Bisoprolol; Female; H | 2018 |
Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2018 |
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
Topics: Aldosterone; Amiloride; Antihypertensive Agents; Bisoprolol; Blood Pressure; Doxazosin; Female; Hemo | 2018 |
Effect of perindopril and bisoprolol on IL-2, INF-γ, hs-CRP and T-cell stimulation and correlations with blood pressure in mild and moderate hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2018 |
Pregnancy outcome after first trimester exposure to bisoprolol: an observational cohort study.
Topics: Abortion, Spontaneous; Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Birth Weight; Biso | 2018 |
Topics: Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Drug Therapy, Combination; Humans; Hypertensio | 2018 |
Simultaneous transient global amnesia and Takotsubo syndrome after death of a relative: a case report.
Topics: Amnesia, Transient Global; Antihypertensive Agents; Aspirin; Atorvastatin; Benzimidazoles; Biphenyl | 2019 |
Modulation of Sympathetic Activity and Innervation With Chronic Ivabradine and β-Blocker Therapies: Analysis of Hypertensive Rats With Heart Failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Bisoprolol; Cardiovascular Agents; Disease Models, | 2019 |
Severe hypoglycemia following massive ischemic stroke in a cannabis-addicted patient treated by a beta-blocking agent.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Antihypertensive Agents; Bisoprolol; Brain Edema; Car | 2019 |
[Telangiectasia during amlodipine therapy].
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Calcium Channel Blockers; Drug Substitution; Drug T | 2013 |
Atrial fibrillation.
Topics: Aged; Antihypertensive Agents; Anxiety; Atrial Fibrillation; Bisoprolol; Comorbidity; Diabetes Melli | 2013 |
[The effect of amlodipine, bisoprolol on the myocardial ultrastructure of the hypertensive rats].
Topics: Amlodipine; Animals; Antihypertensive Agents; Bisoprolol; Blood Pressure; Capillaries; Drug Combinat | 2013 |
[Digital necrosis in hand by uncommon mechanism].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Analgesics, Non-Narcotic; Bisoprolol; Caffeine; Centr | 2013 |
Young woman with idiopathic supradiaphragmatic mid-aortic syndrome and hypertension successfully controlled with a beta-blocker-calcium antagonist fixed-dose combination.
Topics: Adrenergic beta-1 Receptor Antagonists; Amlodipine; Aorta, Abdominal; Aortic Arch Syndromes; Bisopro | 2013 |
[Intraoperative anaphylaxis due to beta-lactams in a hypertensive patient on angiotensin ii receptor antagonists and beta-blockers].
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anaphylaxis; Angiotensin II Type 1 Receptor Blockers; | 2015 |
[Evaluating the effectiveness of a fixed combination of amlodipine and bisoprolol in ambulatory patients with arterial hypertension and ischemic heart disease].
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Amlodipine; Bisoprolol; Blood Pressure; Calcium Channe | 2014 |
Benefits of a fixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Dru | 2015 |
Comparison of atenolol versus bisoprolol with noninvasive hemodynamic and pulse wave assessment.
Topics: Anthropometry; Antihypertensive Agents; Atenolol; Biomarkers; Bisoprolol; Cardiography, Impedance; C | 2015 |
Transdermal patch of bisoprolol for the treatment of hypertension complicated with aortic dissection.
Topics: Antihypertensive Agents; Aortic Aneurysm; Aortic Dissection; Bisoprolol; Humans; Hypertension; Male; | 2015 |
Intraventricular aberrancy, pseudo-supernormality and intrahisian conduction "gap" in premature junctional beats.
Topics: Aged; Antihypertensive Agents; Bisoprolol; Bundle-Branch Block; Cardiac Complexes, Premature; Cathet | 2015 |
Spironolactone for resistant hypertension--hard to resist?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2015 |
Hypertension: PATHWAY to improving the treatment of drug-resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2015 |
ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2016 |
[Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension].
Topics: Antihypertensive Agents; Bisoprolol; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; Spi | 2016 |
PATHWAY-2: spironolactone for resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2016 |
PATHWAY-2: spironolactone for resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2016 |
PATHWAY-2: spironolactone for resistant hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2016 |
PATHWAY-2: spironolactone for resistant hypertension - Authors' reply.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazos | 2016 |
Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; | 2016 |
Heart rate dependent and independent effects of beta-blockers on central hemodynamic parameters: a propensity score analysis.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atenolol; Bisoprolol; Blood Pressure; Cross-Sectional | 2016 |
Possible relationship between certolizumab pegol and arrhythmias: report of two cases.
Topics: Aged; Antirheumatic Agents; Arrhythmias, Cardiac; Arthritis, Rheumatoid; Bisoprolol; Certolizumab Pe | 2016 |
Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Clinical Trials as Topic; Drug Combinations; Humans | 2017 |
A Fixed-Dose Combination of Bisoprolol and Amlodipine for Hypertension: A Potential Benefit to Selected Patients.
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Humans; Hypertension | 2017 |
[Psychological Characteristics of Patients With Stress-induced Arterial Hypertension: a Violation of the Regulation of Emotions as a Central Link of Pathogenesis].
Topics: Acrylates; Adult; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Pressure Determination; | 2016 |
[The Fixed Combination of Amlodipine and Bisoprolol Eliminates the Effect of -Blockers on Central Pulse Wave in Patients With Arterial Hypertension].
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Pressure Determination; Drug | 2015 |
[Comparative Assessment of Effects of Free and Fixed Combinations of Hypotensive Drugs on Quality of Life of Patients With Arterial Hypertension of High and Very High Risk].
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Female; Humans; Hypertension; Indap | 2016 |
Silica in oral drugs as a possible sarcoidosis-inducing antigen.
Topics: Administration, Oral; Antigens; Antihypertensive Agents; Bisoprolol; Causality; Chemistry, Pharmaceu | 2009 |
[Efficacy and safety of bisoprolol in pregnant women with chronic arterial hypertension do not depend on genetic CYP2D6 polymorphism].
Topics: Adult; Antihypertensive Agents; Bisoprolol; Blood Pressure; Cytochrome P-450 CYP2D6; DNA; Female; Hu | 2009 |
Is overall blockade superior to selective blockade of adrenergic receptor subtypes in suppressing left ventricular remodeling in spontaneously hypertensive rats?
Topics: Adrenergic Antagonists; Animals; Apoptosis; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Dise | 2010 |
A critical role of sympathetic nerve regulation for the treatment of impaired daily rhythm in hypertensive Dahl rats.
Topics: Animals; Antihypertensive Agents; Bisoprolol; Blood Pressure; Circadian Rhythm; Disease Models, Anim | 2010 |
Combined blockade of β- and α₁-adrenoceptors in left ventricular remodeling induced by hypertension: beneficial or not?
Topics: Adrenergic Antagonists; Animals; Bisoprolol; Carbazoles; Carvedilol; Disease Models, Animal; Humans; | 2010 |
[Urinary bladder tuberculosis and bacillus calmette-guérin instillation: reduced efficacy of bisoprolol in hypertension].
Topics: Aged; Antihypertensive Agents; Antitubercular Agents; BCG Vaccine; Bisoprolol; Carcinoma, Transition | 2010 |
STK39 variation predicts the ambulatory blood pressure response to losartan in hypertensive men.
Topics: Adult; Alleles; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Pressure Moni | 2012 |
[Elevated augmentation index].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Bisoprolol; Blood Pressure; Carbazole | 2012 |
[Combined low-dose antihypertensive therapy in pregnant women with hypertension and preeclampsia].
Topics: Adult; Antihypertensive Agents; Bisoprolol; Blood Pressure; Chronic Disease; Dose-Response Relations | 2012 |
Short-term antihypertensive therapy lowers the C-reactive protein level.
Topics: Adult; Antihypertensive Agents; Biomarkers; Bisoprolol; Blood Pressure; C-Reactive Protein; Drug Adm | 2012 |
Hypotensive and heart rate-lowering effects of low-dose bisoprolol determined based on self-measured blood pressure at home.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Blood Pressure; B | 2012 |
A retrospective in vitro study of the impact of anti-diabetics and cardioselective pharmaceuticals on breast cancer.
Topics: Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Blood Glucose; Breast Neoplasms; Cell Line, Tumo | 2012 |
[Broadened indications for the use of selective β-adrenoblockers].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Calcium Channel Blockers; Female; | 2012 |
[Potentialities of medicinal correction of cerebrovascular disturbances in patients with arterial hypertension].
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Cerebrovascular Disorders; Drug Therapy, Combinatio | 2012 |
Functional beta1- and beta2-adrenoceptors in the left and right atrium of pre-hypertensive rats.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Recep | 2002 |
[Assessment of acute blood pressure variability during a stress test].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2002 |
Effects of exercise and beta-blocker on blood pressure and baroreflexes in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Baroreflex; Bisoprolol; Blood Pressure; Body Weight; | 2003 |
Which beta-blocker for heart failure?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Coronary Disease | 2004 |
Activation of capsaicin-sensitive sensory neurons by carvedilol, a nonselective beta-blocker, in spontaneous hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Bisoprolol; Blood Pressure; Calc | 2004 |
Bisoprolol and hydrochlorothiazide effects on cardiovascular remodeling in spontaneously hypertensive rats.
Topics: Animals; Bisoprolol; Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug T | 2005 |
Repeated intensification of lower urinary tract symptoms in the patient with benign prostatic hyperplasia during bisoprolol treatment.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Humans; Hypertension; Male; Middle | 2005 |
[Primary prophylaxis of cerebrovascular complications in patients with metabolic syndrome].
Topics: Adult; Antihypertensive Agents; Bisoprolol; Brain; Carbohydrate Metabolism; Cerebrovascular Circulat | 2005 |
Bisoprolol improves echocardiographic parameters of left ventricular diastolic function in patients with systemic hypertension.
Topics: Antihypertensive Agents; Bisoprolol; Echocardiography; Female; Heart Ventricles; Humans; Hypertensio | 2006 |
Ethanol-induced coma after therapeutic ethanol injection of a hepatic cyst.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Coma; Cysts; Ethanol; Female; Humans; Hypertension; L | 2008 |
[Level of hormones of pituitary-gonadal axis, penile blood flow and sexual function in men with arterial hypertension during monotherapy with bisoprolol and nebivolol].
Topics: Adrenergic beta-Antagonists; Adult; Benzopyrans; Bisoprolol; Blood Flow Velocity; Blood Pressure; Dr | 2007 |
Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats.
Topics: Adrenergic beta-Antagonists; Animals; Bisoprolol; Disease Models, Animal; Dose-Response Relationship | 2008 |
[Clinical efficacy of antihypertensive therapy of pregnant women with arterial hypertension with long acting nifedipine and bisoprolol].
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Blood Pressure; Calcium Channel Blockers; Delayed-Ac | 2008 |
Vasoconstrictors and renal protection induced by beta 1-selective adrenoceptor antagonist bisoprolol.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Bisoprolol; Blood Pres | 1994 |
Antihypertensive monotherapy and stress-induced changes in physiological activity.
Topics: Adult; Aged; Antihypertensive Agents; Bisoprolol; Blood Pressure; Electrophysiology; Enalapril; Fema | 1993 |
Bisoprolol-induced nightmares.
Topics: Adult; Bisoprolol; Dreams; Female; Humans; Hypertension | 1994 |
Functional beta-adrenoceptors in the left atrium of normotensive and hypertensive rats.
Topics: Animals; Atrial Function; Bisoprolol; Calcium Chloride; Ethanolamines; Heart Atria; Hypertension; Is | 1994 |
Combination products as first-line pharmacotherapy.
Topics: Betaxolol; Bisoprolol; Chlorthalidone; Drug Approval; Drug Combinations; Humans; Hydrochlorothiazide | 1994 |
Life survival and cardiovascular structures following selective beta-blockade in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Aging; Animals; Arteries; Bisoprolol; Blood Pressure; Body Weight; Card | 1994 |
Remembering the lessons of basic pharmacology.
Topics: Bisoprolol; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hydrochlorothiazide; Hypert | 1994 |
Ziac for hypertension.
Topics: Bisoprolol; Clinical Trials as Topic; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension | 1994 |
[Bisoprolol in the treatment of hypertension].
Topics: Bisoprolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged | 1993 |
Effects of antihypertensive therapy on left ventricular hypertrophy of essential hypertension: a role for insulin-like growth factor I?
Topics: Adult; Aged; Antihypertensive Agents; Bisoprolol; Captopril; Echocardiography; Female; Humans; Hyper | 1993 |
[Improvement of coronary reserve following regression of hypertrophy resulting from blood pressure lowering therapy with a beta-receptor blocker].
Topics: Adult; Argon; Bisoprolol; Cardiomegaly; Chromatography, Gas; Coronary Circulation; Female; Hemodynam | 1993 |
[Hypertriglyceridemia secondary to bisoprolol treatment].
Topics: Adult; Bisoprolol; Female; Humans; Hypertension; Hypertriglyceridemia; Triglycerides | 1993 |
Bisoprolol launched in South Africa.
Topics: Antihypertensive Agents; Bisoprolol; Drug Administration Schedule; Humans; Hypertension | 1996 |
A new antihypertensive strategy for black patients: low-dose multimechanism therapy.
Topics: Antihypertensive Agents; Bisoprolol; Black or African American; Clinical Trials as Topic; Drug Thera | 1996 |
[Drug of the month. Maxsoten].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Drug Combinations; Humans; Hydroch | 1996 |
The effects of 2 beta-receptor blocking agents on the microcirculation of healthy subjects and of hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Visco | 1997 |
Objectives of high blood pressure treatment: left ventricular hypertrophy, diastolic function, and coronary reserve.
Topics: Antihypertensive Agents; Arterioles; Bisoprolol; Blood Pressure; Coronary Circulation; Diastole; Dil | 1998 |
Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Bisoprolol; C | 1998 |
[A case of typical flushing of atypical origin].
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Cardiac Complexes, Premature; Flushing; Humans; Hyper | 1999 |
Bisoprolol-induced rapid eye movement sleep behavior disorder.
Topics: Antihypertensive Agents; Bisoprolol; Female; Humans; Hypertension; Male; Middle Aged; Polysomnograph | 1999 |
Bisoprolol-induced rapid eye movement sleep behavior disorder.
Topics: Antihypertensive Agents; Bisoprolol; Female; Humans; Hypertension; Male; Middle Aged; Polysomnograph | 1999 |
Bisoprolol-induced rapid eye movement sleep behavior disorder.
Topics: Antihypertensive Agents; Bisoprolol; Female; Humans; Hypertension; Male; Middle Aged; Polysomnograph | 1999 |
Bisoprolol-induced rapid eye movement sleep behavior disorder.
Topics: Antihypertensive Agents; Bisoprolol; Female; Humans; Hypertension; Male; Middle Aged; Polysomnograph | 1999 |
Pharmacokinetics of bisoprolol and its effect on dialysis refractory hypertension.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; | 1999 |
[New indications for beta blockers. Cave hypertension focus/heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; D | 2000 |
Anti beta1-adrenoceptor autoantibodies analyzed in spontaneously beating neonatal rat heart myocyte cultures-comparison of methods.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Autoantibodies; Bi | 2001 |
[Hypertensive diabetic patients. Plus points for selective beta 1-blockade].
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Bisopr | 2001 |
Three years of experience with bisoprolol in the treatment of mild to moderate hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Glucose; Blood Pressure; Cho | 1990 |
Age dependence of therapy result and risk in the treatment of arterial hypertension?
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Bisoprolol; Blood Pressure; Female; Heart Rat | 1990 |
Cardiovascular reactivity to and renal impact of stress and exercise: effects of bisoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Albuminuria; Bisoprolol; Blood Pressure; Catecholamines; Exercis | 1990 |
Prevention of stress-induced hypertension in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Pressure; Blood Pressure Monitoring, Amb | 1990 |
[Management of essential arterial hypertension].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2000 |
[Beta blockers for hypertension. No negative influence on insulin resistance].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Clinical Trials as Topic; Humans; | 2002 |
Perindopril reverses myocyte remodeling in the hypertensive heart.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bisoprolol; Cell Cou | 2002 |
[The effect of a single dose of Bisoprolol on changes in blood pressure and hemodynamic indicators in patients with mild hypertension].
Topics: Bisoprolol; Blood Pressure; Hemodynamics; Humans; Hypertension; Middle Aged | 1992 |
[The effect of a single dose of Bisoprolol on changes in blood pressure and hemodymic indicators in patients with mild hypertension during loading].
Topics: Bisoprolol; Blood Pressure; Exercise Test; Hemodynamics; Humans; Hypertension; Middle Aged | 1992 |
Effect of beta-blockade on albumin excretion rate in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Albuminuria; Bisoprolol; Female; Glomerular Filtration Rat | 1990 |
[Outcome of "white coat reaction" induced by nurse and physician in patients with hypertension treated with a beta blockader (bisoprolol)].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Ambulatory Care; Bisoprolol; Blood Pressure; Blood Pressur | 1990 |
Optimization of beta-blockers for cardiovascular care. International Bisoprolol Symposium. Rabat, Morocco, November 20-22, 1985.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Heart Diseases; Humans; Hypertension; Propanolamines | 1986 |
Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cholesterol in patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Blood Pressure; Cholesterol, HDL; Female; Heart Rate | 1986 |
High beta 1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol.
Topics: Adrenergic beta-Antagonists; Anesthesia; Anesthetics, Local; Animals; Bisoprolol; Blood Vessels; Cat | 1986 |
Noninvasive assessment of left ventricular performance after administration of bisoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Blood Pressure; Echocardiography; Exercise Test; Hea | 1986 |
[A new beta 1-receptor blocker in the therapy of essential hypertension and angina pectoris].
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Bisoprolol; Female; Hemodynamics; Humans; Hypert | 1989 |
Bisoprolol--another cardioselective beta blocker.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Bisoprolol; Humans; Hypertension; Propanolamines | 1989 |
Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Blood Pressure; Cholesterol, HDL; Female; Humans; Hy | 1987 |
Duration of action of bisoprolol after cessation of a 4 week treatment and its influence on pulse wave velocity and aortic diameter: a pilot study in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aorta, Abdominal; Bisoprolol; Blood Flow Velocity; Blood Pressur | 1987 |